{"PMC7280667": [["Rapid communication with experts via Twitter ::: INTRODUCTIONIn the weeks after declaration of a global pandemic when governmental agencies and professional organizations were struggling to provide safe and practical recommendations, the responsibility for weighing the risk of COVID\u201019 exposure to their patients (and staff) and the risks of deferred medical care was also taken up by the physicians.", [["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 305, 313]]], ["For rapid exchange of information and communication with fellow physicians and specialists with certain expertise, many were reliant on social media, especially Twitter.6Herein, we will summarize the views, concerns and priorities expressed by many experienced specialists during three different discussions that took place on Twitter within 4 days.", [["6Herein", "SIMPLE_CHEMICAL", 169, 176]]], ["Discussions included practice patterns for prostate cancer (PCa) and bladder cancer management in the context of COVID\u201019 related constraints on medical care.", [["prostate cancer", "ANATOMY", 43, 58], ["PCa", "ANATOMY", 60, 63], ["bladder cancer", "ANATOMY", 69, 83], ["prostate cancer", "DISEASE", 43, 58], ["PCa", "DISEASE", 60, 63], ["bladder cancer", "DISEASE", 69, 83], ["prostate cancer", "CANCER", 43, 58], ["PCa", "CANCER", 60, 63], ["bladder cancer", "CANCER", 69, 83], ["prostate cancer", "PROBLEM", 43, 58], ["PCa)", "TREATMENT", 60, 64], ["bladder cancer management", "TREATMENT", 69, 94], ["COVID\u2010", "TREATMENT", 113, 119], ["medical care", "TREATMENT", 145, 157], ["prostate", "ANATOMY", 43, 51], ["cancer", "OBSERVATION", 52, 58], ["bladder", "ANATOMY", 69, 76], ["cancer", "OBSERVATION", 77, 83]]], ["Some of the discussion and comments of the participants, with the strength or frequency of recommendations are presented graphically in Figure 1.Prostate cancer ::: INTRODUCTIONOne of the earlier discussion was initiated by an urologist seeking opinions about prioritization of treatment of a 56 year old with multifocal high\u2010grade PCa, Grade group (GG) 4 and 3.", [["Prostate cancer", "ANATOMY", 145, 160], ["PCa", "ANATOMY", 332, 335], ["Prostate cancer", "DISEASE", 145, 160], ["PCa", "DISEASE", 332, 335], ["Prostate cancer", "CANCER", 145, 160], ["high\u2010grade PCa", "CANCER", 321, 335], ["participants", "SPECIES", 43, 55], ["Prostate cancer", "PROBLEM", 145, 160], ["treatment", "TREATMENT", 278, 287], ["multifocal high\u2010grade PCa", "PROBLEM", 310, 335], ["Grade group (GG)", "PROBLEM", 337, 353], ["cancer", "OBSERVATION", 154, 160], ["multifocal", "OBSERVATION_MODIFIER", 310, 320], ["PCa", "ANATOMY", 332, 335]]], ["The discussion was joined by a number of experts from various specialties with comments revolving around the timing and type of treatment, including the rationale for their particular approach.", [["treatment", "TREATMENT", 128, 137]]], ["This discussion (and other discussions below) took place in mid\u2010March and should be viewed in the context of early stages of COVID\u201019 in some countries relative to Italy and Spain (Table 1).", [["COVID", "DISEASE", 125, 130], ["COVID\u2010", "TREATMENT", 125, 131], ["mid", "ANATOMY_MODIFIER", 60, 63]]], ["It was nearly uniformly agreed that intermediate risk PCa treatment should be safe to defer for 6 months without any oncological harm.Prostate cancer ::: INTRODUCTIONFor high\u2010risk disease, the rationale provided by some participants for proceeding with surgery was that, at the moment, the healthcare system is not overburdened, and a minimally invasive procedure will not excessively strain the resources.", [["PCa", "ANATOMY", 54, 57], ["Prostate cancer", "ANATOMY", 134, 149], ["PCa", "DISEASE", 54, 57], ["Prostate cancer", "DISEASE", 134, 149], ["PCa", "CANCER", 54, 57], ["Prostate cancer", "CANCER", 134, 149], ["participants", "SPECIES", 220, 232], ["intermediate risk PCa treatment", "TREATMENT", 36, 67], ["any oncological harm", "PROBLEM", 113, 133], ["Prostate cancer", "PROBLEM", 134, 149], ["high\u2010risk disease", "PROBLEM", 170, 187], ["surgery", "TREATMENT", 253, 260], ["a minimally invasive procedure", "TREATMENT", 333, 363], ["cancer", "OBSERVATION", 143, 149]]], ["Some participants were adamantly opposed to any intervention in this scenario so that all PPE could be preserved for the potential surge in COVID\u201019 cases.", [["participants", "SPECIES", 5, 17], ["any intervention", "TREATMENT", 44, 60], ["all PPE", "TREATMENT", 86, 93]]], ["Others expressed concerns over the potential risk of COVID\u201019 exposure during surgery to themselves and to the medical staff from an asymptomatic, untested patient.", [["patient", "ORGANISM", 156, 163], ["patient", "SPECIES", 156, 163], ["surgery", "TREATMENT", 78, 85]]], ["It was discussed that testing the patients for COVID\u201019 virus before surgery could relieve some of these concerns, however, the tests are in short supply and not available for wider use.", [["patients", "ORGANISM", 34, 42], ["COVID\u201019 virus", "ORGANISM", 47, 61], ["patients", "SPECIES", 34, 42], ["COVID\u201019 virus", "SPECIES", 47, 61], ["testing", "TEST", 22, 29], ["COVID\u201019 virus", "TREATMENT", 47, 61], ["surgery", "TREATMENT", 69, 76], ["the tests", "TEST", 124, 133]]], ["Some raised concerns that while it may be safe for a young patient with high\u2010grade cancer to wait 3 months, it's unclear how long the pandemic\u2010related restrictions are going to last.", [["cancer", "ANATOMY", 83, 89], ["cancer", "DISEASE", 83, 89], ["patient", "ORGANISM", 59, 66], ["high\u2010grade cancer", "CANCER", 72, 89], ["patient", "SPECIES", 59, 66], ["high\u2010grade cancer", "PROBLEM", 72, 89]]], ["Their rationale to complete as much of the essential cancer treatment as possible before the anticipated surge in infections results in prolonged, open\u2010ended delays.", [["cancer", "ANATOMY", 53, 59], ["cancer", "DISEASE", 53, 59], ["infections", "DISEASE", 114, 124], ["cancer", "CANCER", 53, 59], ["the essential cancer treatment", "TREATMENT", 39, 69], ["infections", "PROBLEM", 114, 124], ["prolonged, open\u2010ended delays", "PROBLEM", 136, 164], ["cancer", "OBSERVATION", 53, 59]]], ["Their rationale was supported by providing peer\u2010reviewed literature and real\u2010time data such as availability of beds and PPE supplies from various medical centers.10,11The opinions, ranged from absolute no PCa surgery to cautiously proceeding with surgery, with daily assessment of the local situation in that hospital or region.Change in practice pattern ::: INTRODUCTIONBecause of the variety of opinions noted during the above discussion, we asked urologic oncologists whether their own practice of PCa management had changed, or will change, due to COVID\u201019.", [["PCa", "ANATOMY", 205, 208], ["PCa", "ANATOMY", 501, 504], ["PCa", "DISEASE", 205, 208], ["PCa", "DISEASE", 501, 504], ["PCa", "CANCER", 205, 208], ["PCa", "CANCER", 501, 504], ["PPE supplies", "TREATMENT", 120, 132], ["PCa surgery", "TREATMENT", 205, 216], ["surgery", "TREATMENT", 247, 254], ["daily assessment", "TEST", 261, 277], ["PCa management", "TREATMENT", 501, 515]]], ["Specifically, would they consider delaying PCa surgery or consider radiation therapy (RT) instead of surgery or would they consider adding androgen deprivation therapy (ADT) when delaying surgery.", [["PCa", "ANATOMY", 43, 46], ["PCa", "DISEASE", 43, 46], ["androgen", "CHEMICAL", 139, 147], ["PCa", "CANCER", 43, 46], ["androgen", "SIMPLE_CHEMICAL", 139, 147], ["PCa surgery", "TREATMENT", 43, 54], ["radiation therapy", "TREATMENT", 67, 84], ["surgery", "TREATMENT", 101, 108], ["androgen deprivation therapy", "TREATMENT", 139, 167], ["ADT", "TREATMENT", 169, 172], ["delaying surgery", "TREATMENT", 179, 195]]], ["The discussants generally agreed that surgery for patients with intermediate\u2010risk PCa can be safely delayed for 6 months.", [["PCa", "ANATOMY", 82, 85], ["PCa", "DISEASE", 82, 85], ["patients", "ORGANISM", 50, 58], ["PCa", "CANCER", 82, 85], ["patients", "SPECIES", 50, 58], ["surgery", "TREATMENT", 38, 45], ["patients with intermediate\u2010risk PCa", "TREATMENT", 50, 85]]], ["Others opined that since the potential duration of this pandemic is unknown and for some patients, it may already be 3 months since diagnosis, waiting for another 3\u20106 months could lead to adverse outcomes.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["adverse outcomes", "PROBLEM", 188, 204]]], ["This concern was further amplified for patients with high\u2010risk PCa.", [["PCa", "ANATOMY", 63, 66], ["PCa", "DISEASE", 63, 66], ["patients", "ORGANISM", 39, 47], ["high\u2010risk PCa", "CANCER", 53, 66], ["patients", "SPECIES", 39, 47], ["high\u2010risk PCa", "TREATMENT", 53, 66]]], ["The proponents of delayed surgery pointed to publications that delayed surgery was not associated with increased risk of biochemical recurrence.12This was rebutted by another participant that only 5% of patients in that study had high\u2010risk PCa and only 7% were delayed for more than 6 months.", [["PCa", "ANATOMY", 240, 243], ["PCa", "DISEASE", 240, 243], ["patients", "ORGANISM", 203, 211], ["PCa", "CANCER", 240, 243], ["patients", "SPECIES", 203, 211], ["delayed surgery", "TREATMENT", 18, 33], ["delayed surgery", "TREATMENT", 63, 78], ["biochemical recurrence", "PROBLEM", 121, 143], ["that study", "TEST", 215, 225], ["high\u2010risk PCa", "TREATMENT", 230, 243], ["biochemical", "OBSERVATION_MODIFIER", 121, 132], ["recurrence", "OBSERVATION", 133, 143]]], ["The question about using neoadjuvant ADT to make it safer to delay surgery was met with spirited discussion.", [["neoadjuvant ADT", "TREATMENT", 25, 40], ["delay surgery", "TREATMENT", 61, 74]]], ["Some viewed using ADT for delayed surgery as merely providing peace of mind for the patient and the physician, but without any oncological benefit, citing a lack of strong evidence of benefits of neoadjuvant ADT.", [["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["ADT", "TREATMENT", 18, 21], ["delayed surgery", "TREATMENT", 26, 41], ["neoadjuvant ADT", "TREATMENT", 196, 211]]], ["It was suggested that using ADT for delaying surgery for high\u2010risk PCa, especially if the anticipated delay is going to be more than 3 or 6 months, is a safe intermediary which could make it easier to accept the delays.", [["PCa", "ANATOMY", 67, 70], ["PCa", "DISEASE", 67, 70], ["PCa", "CANCER", 67, 70], ["ADT", "TREATMENT", 28, 31], ["surgery", "TREATMENT", 45, 52], ["high\u2010risk PCa", "TREATMENT", 57, 70]]], ["Concerns were raised about ADT\u2010related adverse effects which can be quite pronounced in some patients.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["ADT\u2010related adverse effects", "PROBLEM", 27, 54]]], ["Other respondents viewed neoadjuvant ADT as comparable to the current standard of care of using ADT before RT.", [["neoadjuvant ADT", "TREATMENT", 25, 40], ["ADT", "TREATMENT", 96, 99], ["RT", "TREATMENT", 107, 109]]], ["They referenced a randomized trial showing no significant adverse effects from using short\u2010term neoadjuvant ADT before surgery.13Use of RT was discussed as an alternative to surgery to avoid the oncological risks of delayed treatment and the risk of COVID\u201019 to the surgical team.", [["a randomized trial", "TEST", 16, 34], ["significant adverse effects", "PROBLEM", 46, 73], ["short\u2010term neoadjuvant ADT", "TREATMENT", 85, 111], ["surgery", "TREATMENT", 119, 126], ["RT", "TREATMENT", 136, 138], ["surgery", "TREATMENT", 174, 181], ["delayed treatment", "TREATMENT", 216, 233]]], ["At a time when resource conservation and COVID\u201019 exposure mitigation are overriding concerns, it was debated whether the use of medical resources and risk of exposure was higher during roughly 40 visits to the facility for RT as compared to overnight hospitalization for minimally invasive surgery.", [["resource conservation", "TREATMENT", 15, 36], ["COVID\u201019 exposure mitigation", "TREATMENT", 41, 69], ["medical resources", "TREATMENT", 129, 146], ["RT", "TREATMENT", 224, 226], ["minimally invasive surgery", "TREATMENT", 272, 298]]], ["While radiation oncology colleagues offered changing the practice to hypofractionated RT in 20 fractions, many discussants (mostly urologic oncologists) did not view that approach as having a lower risk of exposure or resource utilization.", [["the practice", "TREATMENT", 53, 65], ["hypofractionated RT in 20 fractions", "TREATMENT", 69, 104], ["resource utilization", "TREATMENT", 218, 238]]], ["Many participants suggested that for high\u2010risk PCa, surgery or RT may proceed if local circumstances are permissive.", [["PCa", "ANATOMY", 47, 50], ["PCa", "DISEASE", 47, 50], ["PCa", "CANCER", 47, 50], ["participants", "SPECIES", 5, 17], ["high\u2010risk PCa", "TREATMENT", 37, 50], ["surgery", "TREATMENT", 52, 59], ["RT", "TREATMENT", 63, 65]]], ["But if anticipated delay is more than 6 months from diagnosis of high\u2010risk PCA, some suggested that the use of ADT may be discussed for a possible, but unproven oncological benefit due to its well\u2010understood safety profile.Change in practice pattern ::: INTRODUCTIONOn March 16, a pre\u2010print of guidance from a group of medical oncologists was presented on Twitter on the timing of chemotherapy for MIBC.", [["MIBC", "ANATOMY", 398, 402], ["MIBC", "DISEASE", 398, 402], ["MIBC", "CANCER", 398, 402], ["high\u2010risk PCA", "PROBLEM", 65, 78], ["ADT", "TREATMENT", 111, 114], ["chemotherapy", "TREATMENT", 381, 393], ["MIBC", "PROBLEM", 398, 402]]], ["They suggested that NAC could be offered to allow safer postponement of surgery.", [["NAC", "CHEMICAL", 20, 23], ["NAC", "CHEMICAL", 20, 23], ["NAC", "SIMPLE_CHEMICAL", 20, 23], ["NAC", "TREATMENT", 20, 23], ["surgery", "TREATMENT", 72, 79]]], ["The claim of safety of NAC lead several respondents to question the wisdom of giving immunosuppressive treatment during a highly infectious pandemic, especially a treatment which is not curative.", [["NAC", "CHEMICAL", 23, 26], ["NAC", "CHEMICAL", 23, 26], ["NAC", "SIMPLE_CHEMICAL", 23, 26], ["NAC lead", "TREATMENT", 23, 31], ["immunosuppressive treatment", "TREATMENT", 85, 112], ["a treatment", "TREATMENT", 161, 172], ["infectious", "OBSERVATION_MODIFIER", 129, 139]]], ["Concerns were raised about losing the curative window of time if the pandemic worsens while receiving NAC.", [["NAC", "CHEMICAL", 102, 105], ["NAC", "CHEMICAL", 102, 105], ["NAC", "SIMPLE_CHEMICAL", 102, 105], ["the pandemic worsens", "PROBLEM", 65, 85], ["NAC", "TREATMENT", 102, 105]]], ["Another poll conducted by a group of GU medical oncologists on March 18 about anticipated changes due to COVID\u201019 in the management of cisplatin\u2010eligible stage T3 bladder cancer.", [["cisplatin\u2010eligible stage T3 bladder cancer", "ANATOMY", 135, 177], ["bladder cancer", "DISEASE", 163, 177], ["cisplatin\u2010eligible stage T3 bladder cancer", "CANCER", 135, 177], ["COVID\u2010", "TREATMENT", 105, 111], ["cisplatin\u2010eligible stage T3 bladder cancer", "PROBLEM", 135, 177], ["T3", "OBSERVATION_MODIFIER", 160, 162], ["bladder", "ANATOMY", 163, 170], ["cancer", "OBSERVATION", 171, 177]]], ["Nearly 60% of 78 respondents would use the standard protocol of NAC and surgery while 37% preferred either surgery alone or with adjuvant chemotherapy.", [["NAC", "CHEMICAL", 64, 67], ["NAC", "CHEMICAL", 64, 67], ["NAC", "SIMPLE_CHEMICAL", 64, 67], ["the standard protocol of NAC", "TREATMENT", 39, 67], ["surgery", "TREATMENT", 72, 79], ["surgery", "TREATMENT", 107, 114], ["adjuvant chemotherapy", "TREATMENT", 129, 150]]], ["This suggested that roughly 1/3 of the respondents would potentially change their practice of NAC due to COVID\u201019.Bladder cancer ::: INTRODUCTIONA detailed discussion on March 20 was held to strategize about the safety and effectiveness of various therapeutic sequences to treat muscle invasive (MIBC) and non\u2010muscle invasive (NMIBC) bladder cancer.", [["Bladder cancer", "ANATOMY", 114, 128], ["muscle invasive (MIBC", "ANATOMY", 279, 300], ["non\u2010muscle invasive (NMIBC) bladder cancer", "ANATOMY", 306, 348], ["NAC", "CHEMICAL", 94, 97], ["Bladder cancer", "DISEASE", 114, 128], ["muscle invasive (MIBC) and non\u2010muscle invasive (NMIBC) bladder cancer", "DISEASE", 279, 348], ["NAC", "CHEMICAL", 94, 97], ["NAC", "SIMPLE_CHEMICAL", 94, 97], ["Bladder cancer", "CANCER", 114, 128], ["muscle", "ORGAN", 279, 285], ["MIBC", "CANCER", 296, 300], ["non\u2010muscle invasive (NMIBC) bladder cancer", "CANCER", 306, 348], ["NAC", "TREATMENT", 94, 97], ["Bladder cancer", "PROBLEM", 114, 128], ["various therapeutic sequences", "TREATMENT", 240, 269], ["muscle invasive (MIBC)", "PROBLEM", 279, 301], ["non\u2010muscle invasive (NMIBC) bladder cancer", "PROBLEM", 306, 348], ["cancer", "OBSERVATION", 122, 128], ["muscle", "ANATOMY", 279, 285], ["invasive", "OBSERVATION", 286, 294], ["invasive", "OBSERVATION_MODIFIER", 317, 325], ["NMIBC", "OBSERVATION", 327, 332], ["bladder", "ANATOMY", 334, 341], ["cancer", "OBSERVATION", 342, 348]]], ["Questions were asked about the best course of action for a patient with MIBC who finished neoadjuvant chemotherapy (NAC) 1 month ago and was scheduled for radical cystectomy in 2 weeks.", [["MIBC", "DISEASE", 72, 76], ["patient", "ORGANISM", 59, 66], ["MIBC", "CANCER", 72, 76], ["patient", "SPECIES", 59, 66], ["MIBC", "TREATMENT", 72, 76], ["neoadjuvant chemotherapy (NAC)", "TREATMENT", 90, 120], ["radical cystectomy", "TREATMENT", 155, 173], ["cystectomy", "OBSERVATION", 163, 173]]], ["Should that surgery be postponed due to potential shortage of supplies or should the surgery proceed as scheduled, before there is a COVID\u201019 surge resulting in delay of 3\u20106 months?", [["surgery", "TREATMENT", 12, 19], ["the surgery", "TREATMENT", 81, 92]]], ["Several of the uro\u2010oncologists recommended proceeding with the definitive excision and utilize early recovery pathways for short hospitalization since the treatment offers the best chance at cure and delayed surgery is associated with worse survival outcomes.Bladder cancer ::: INTRODUCTIONIn a follow\u2010up discussion on March 22, participants from various sub\u2010specialties were queried about their preferred therapeutic sequence for stage T2 MIBC including surgery and/or chemotherapy and/or RT.", [["Bladder cancer", "ANATOMY", 259, 273], ["Bladder cancer", "DISEASE", 259, 273], ["MIBC", "DISEASE", 440, 444], ["Bladder cancer", "CANCER", 259, 273], ["participants", "SPECIES", 329, 341], ["the definitive excision", "TREATMENT", 59, 82], ["the treatment", "TREATMENT", 151, 164], ["delayed surgery", "TREATMENT", 200, 215], ["worse survival outcomes", "PROBLEM", 235, 258], ["Bladder cancer", "PROBLEM", 259, 273], ["stage T2 MIBC", "PROBLEM", 431, 444], ["surgery", "TREATMENT", 455, 462], ["chemotherapy", "TREATMENT", 470, 482], ["RT", "TREATMENT", 490, 492], ["cancer", "OBSERVATION", 267, 273]]], ["Well over 100 responses within 1 day from dozens of experts about the rationale for their approach, and 320 votes were cast about the preferred initial management.", [["initial management", "TREATMENT", 144, 162]]], ["Interestingly, 44% favored NAC alone (and defer surgery), 41% would proceed with radical cystectomy alone, and 12% choosing primary RT with chemotherapy.", [["NAC", "CHEMICAL", 27, 30], ["NAC", "CHEMICAL", 27, 30], ["NAC", "SIMPLE_CHEMICAL", 27, 30], ["surgery", "TREATMENT", 48, 55], ["radical cystectomy", "TREATMENT", 81, 99], ["chemotherapy", "TREATMENT", 140, 152], ["cystectomy", "OBSERVATION", 89, 99], ["chemotherapy", "OBSERVATION", 140, 152]]], ["The recommendation for postponing radical cystectomy in favor of NAC was to mitigate the risk of COVID\u201019 exposure in the perioperative period.", [["NAC", "CHEMICAL", 65, 68], ["NAC", "CHEMICAL", 65, 68], ["NAC", "SIMPLE_CHEMICAL", 65, 68], ["postponing radical cystectomy", "TREATMENT", 23, 52], ["NAC", "TREATMENT", 65, 68], ["cystectomy", "OBSERVATION", 42, 52]]], ["This idea was predicated on the significantly high utilization of medical resources including PPEs, hospitalization and readmissions due to complications.", [["medical resources", "TREATMENT", 66, 83], ["PPEs", "TREATMENT", 94, 98], ["hospitalization", "TREATMENT", 100, 115], ["complications", "PROBLEM", 140, 153]]], ["It was pointed out that the bladder cancer patients meet all the criteria for being at higher risk for COVID\u201019 infection that is, older age, malignancy etc. And since the majority of adult chemotherapy for solid tumors offers only modest benefit, including MIBC with 5% overall survival improvement, the risks related to NAC may not be justified.14Some participants provided pre\u2010print of guidance developed at their institutions to support their rationale for surgery or NAC taking into account the frequent visits to medial facility for infusion, lab work, possible imaging, blood work, PPE utilization, anesthesia services, and hospital beds.", [["bladder cancer", "ANATOMY", 28, 42], ["solid tumors", "ANATOMY", 207, 219], ["blood", "ANATOMY", 577, 582], ["bladder cancer", "DISEASE", 28, 42], ["COVID", "DISEASE", 103, 108], ["infection", "DISEASE", 112, 121], ["malignancy", "DISEASE", 142, 152], ["tumors", "DISEASE", 213, 219], ["NAC", "CHEMICAL", 322, 325], ["NAC", "CHEMICAL", 472, 475], ["NAC", "CHEMICAL", 322, 325], ["NAC", "CHEMICAL", 472, 475], ["bladder cancer", "CANCER", 28, 42], ["patients", "ORGANISM", 43, 51], ["solid tumors", "CANCER", 207, 219], ["MIBC", "CANCER", 258, 262], ["NAC", "SIMPLE_CHEMICAL", 322, 325], ["NAC", "SIMPLE_CHEMICAL", 472, 475], ["blood", "ORGANISM_SUBSTANCE", 577, 582], ["patients", "SPECIES", 43, 51], ["participants", "SPECIES", 354, 366], ["the bladder cancer", "PROBLEM", 24, 42], ["COVID\u201019 infection", "PROBLEM", 103, 121], ["malignancy", "PROBLEM", 142, 152], ["adult chemotherapy", "TREATMENT", 184, 202], ["solid tumors", "PROBLEM", 207, 219], ["MIBC", "TREATMENT", 258, 262], ["NAC", "TREATMENT", 322, 325], ["surgery", "TREATMENT", 461, 468], ["NAC", "TREATMENT", 472, 475], ["imaging", "TEST", 568, 575], ["blood work", "TEST", 577, 587], ["anesthesia services", "TREATMENT", 606, 625], ["bladder", "ANATOMY", 28, 35], ["cancer", "OBSERVATION", 36, 42], ["infection", "OBSERVATION", 112, 121], ["malignancy", "OBSERVATION", 142, 152], ["tumors", "OBSERVATION", 213, 219]]], ["Radical cystectomy is a major surgery with complicated postoperative course and need for readmission to the hospital in roughly 30% of cases.", [["Radical cystectomy", "TREATMENT", 0, 18], ["a major surgery", "TREATMENT", 22, 37], ["cystectomy", "OBSERVATION", 8, 18]]], ["A published reference was shared showing that cisplatin\u2010based chemotherapy is also associated with ER visits or hospitalization rate of 10%\u201020%.15", [["ER", "GENE_OR_GENE_PRODUCT", 99, 101], ["ER", "PROTEIN", 99, 101], ["cisplatin\u2010based chemotherapy", "TREATMENT", 46, 74], ["hospitalization rate", "TEST", 112, 132]]]], "PMC7228353": [["INTRODUCTIONInfluenza continues to be an important cause of morbidity and mortality worldwide, affecting large segments of the human population each year.", [["human", "ORGANISM", 127, 132], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["morbidity", "PROBLEM", 60, 69], ["morbidity", "OBSERVATION", 60, 69], ["large", "OBSERVATION_MODIFIER", 105, 110], ["segments", "OBSERVATION_MODIFIER", 111, 119]]], ["The illness is determined by an acute respiratory tract infection (ARI), tending to spread quickly in seasonal epidemics.1 Influenza can cause mild diseases or progress to a fatal outcome, particularly for high\u2010risk groups, including children, pregnant women, elderly, immunocompromised patients, and those with chronic underlying diseases.1, 2", [["respiratory tract", "ANATOMY", 38, 55], ["illness", "DISEASE", 4, 11], ["acute respiratory tract infection", "DISEASE", 32, 65], ["ARI", "DISEASE", 67, 70], ["Influenza", "DISEASE", 123, 132], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["children", "ORGANISM", 234, 242], ["women", "ORGANISM", 253, 258], ["patients", "ORGANISM", 287, 295], ["children", "SPECIES", 234, 242], ["women", "SPECIES", 253, 258], ["patients", "SPECIES", 287, 295], ["an acute respiratory tract infection", "PROBLEM", 29, 65], ["ARI", "PROBLEM", 67, 70], ["seasonal epidemics", "PROBLEM", 102, 120], ["Influenza", "PROBLEM", 123, 132], ["mild diseases", "PROBLEM", 143, 156], ["chronic underlying diseases", "PROBLEM", 312, 339], ["illness", "OBSERVATION", 4, 11], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["respiratory tract", "ANATOMY", 38, 55], ["infection", "OBSERVATION", 56, 65], ["mild", "OBSERVATION_MODIFIER", 143, 147], ["diseases", "OBSERVATION", 148, 156], ["diseases", "OBSERVATION", 331, 339]]]], "PMC7267261": [["Human saliva is an inquisitively complex fluid and has an imperative role for prevention and protection from viral infection, particularly through innate immune system, which is a prominent first\u2010line defense against viral infection (Dawes et al., 2015; Malamud et al., 2011).", [["viral infection", "DISEASE", 109, 124], ["viral infection", "DISEASE", 217, 232], ["Human", "ORGANISM", 0, 5], ["saliva", "ORGANISM_SUBSTANCE", 6, 12], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["an inquisitively complex fluid", "PROBLEM", 16, 46], ["protection", "TREATMENT", 93, 103], ["viral infection", "PROBLEM", 109, 124], ["viral infection", "PROBLEM", 217, 232], ["fluid", "OBSERVATION", 41, 46], ["viral infection", "OBSERVATION", 109, 124], ["prominent", "OBSERVATION_MODIFIER", 180, 189], ["viral", "OBSERVATION_MODIFIER", 217, 222], ["infection", "OBSERVATION", 223, 232]]]], "PMC7166354": [["INTRODUCTIONRespiratory infections have long been recognized as a worldwide health problem and a major cause of morbidity and mortality, with infants and young children especially susceptible.1, 2 Among these infections, community\u2010acquired pneumonia (CAP) is the predominant cause of childhood morbidity and mortality, causing nearly 1.2 million deaths each year in children <5 years old.3 In 2015, pneumonia killed 920 136 children under the age of 5 years, accounting for 15% of all deaths of children of this age group.4 Most of these deaths occur in developing countries.", [["INTRODUCTIONRespiratory infections", "DISEASE", 0, 34], ["infections", "DISEASE", 209, 219], ["pneumonia", "DISEASE", 240, 249], ["CAP", "DISEASE", 251, 254], ["deaths", "DISEASE", 346, 352], ["pneumonia", "DISEASE", 399, 408], ["deaths", "DISEASE", 485, 491], ["deaths", "DISEASE", 538, 544], ["infants", "ORGANISM", 142, 149], ["children", "ORGANISM", 160, 168], ["children", "ORGANISM", 366, 374], ["children", "ORGANISM", 424, 432], ["children", "ORGANISM", 495, 503], ["infants", "SPECIES", 142, 149], ["children", "SPECIES", 160, 168], ["children", "SPECIES", 366, 374], ["children", "SPECIES", 424, 432], ["children", "SPECIES", 495, 503], ["INTRODUCTIONRespiratory infections", "PROBLEM", 0, 34], ["these infections", "PROBLEM", 203, 219], ["community\u2010acquired pneumonia (CAP", "PROBLEM", 221, 254], ["childhood morbidity", "PROBLEM", 284, 303], ["pneumonia", "PROBLEM", 399, 408], ["infections", "OBSERVATION", 24, 34], ["morbidity", "OBSERVATION", 112, 121], ["infections", "OBSERVATION", 209, 219], ["pneumonia", "OBSERVATION", 240, 249], ["CAP", "OBSERVATION_MODIFIER", 251, 254], ["predominant cause of", "UNCERTAINTY", 263, 283], ["childhood", "OBSERVATION_MODIFIER", 284, 293], ["morbidity", "OBSERVATION", 294, 303]]], ["In China, there are an estimated 21.1 million new cases of pneumonia annually in children <5 years old.5 Globally, the incidence of pneumonia has probably decreased due to the introduction of pediatric pneumococcal vaccines and Haemophilus influenzae type b (Hib) conjugate vaccines over the past three decades, as well as the decreased rate of smoking in most countries.6, 7, 8, 9, 10, 11 Respiratory viruses are the etiological agent in almost one\u2010third of CAP cases.", [["pneumonia", "DISEASE", 59, 68], ["pneumonia", "DISEASE", 132, 141], ["Haemophilus influenzae type b", "DISEASE", 228, 257], ["smoking", "CHEMICAL", 345, 352], ["Respiratory viruses", "DISEASE", 390, 409], ["CAP", "DISEASE", 459, 462], ["children", "ORGANISM", 81, 89], ["Haemophilus influenzae type b (Hib) conjugate", "ORGANISM", 228, 273], ["children", "SPECIES", 81, 89], ["Haemophilus influenzae", "SPECIES", 228, 250], ["pneumococcal", "SPECIES", 202, 214], ["Haemophilus influenzae", "SPECIES", 228, 250], ["pneumonia", "PROBLEM", 59, 68], ["pneumonia", "PROBLEM", 132, 141], ["pediatric pneumococcal vaccines", "TREATMENT", 192, 223], ["Haemophilus influenzae type b (Hib) conjugate vaccines", "TREATMENT", 228, 282], ["pneumonia", "OBSERVATION", 59, 68], ["pneumonia", "OBSERVATION", 132, 141], ["probably", "UNCERTAINTY", 146, 154], ["decreased", "OBSERVATION_MODIFIER", 155, 164], ["Respiratory viruses", "OBSERVATION", 390, 409]]], ["Globally, it is estimated that 100 million cases of viral pneumonia occur annually.12 The known causative viral pathogens in childhood pneumonia reported are mainly seasonal influenza A and B viruses (IVA and IVB), respiratory syncytial viruses (RSV), parainfluenza viruses 1\u20103 (PIVs 1\u20103), adenovirus (ADV), and human rhinovirus (HRV).13, 14, 15 Advances in molecular detection techniques have facilitated the identification of several novel respiratory viruses, such as human metapneumovirus (HMPV), human bocavirus (HBoV), and human coronavirus.16, 17, 18, 19 More recently, Mycoplasma pneumoniae (M. pneumoniae) has been recognized as the pathogen responsible for mild to severe lower respiratory tract infections in older children.20 Several factors such as age, underlying disease, and environment have a substantial influence on epidemics and outbreaks of respiratory viruses and M. pneumoniae.", [["lower respiratory tract", "ANATOMY", 682, 705], ["pneumonia", "DISEASE", 58, 67], ["pneumonia", "DISEASE", 135, 144], ["influenza A and B viruses", "DISEASE", 174, 199], ["IVA", "CHEMICAL", 201, 204], ["IVB", "DISEASE", 209, 212], ["respiratory syncytial viruses", "DISEASE", 215, 244], ["parainfluenza viruses", "DISEASE", 252, 273], ["respiratory viruses", "DISEASE", 442, 461], ["human metapneumovirus (HMPV), human bocavirus (HBoV), and human coronavirus", "DISEASE", 471, 546], ["Mycoplasma pneumoniae", "DISEASE", 577, 598], ["lower respiratory tract infections", "DISEASE", 682, 716], ["respiratory viruses", "DISEASE", 862, 881], ["B viruses", "ORGANISM", 190, 199], ["respiratory syncytial viruses", "ORGANISM", 215, 244], ["RSV", "ORGANISM", 246, 249], ["parainfluenza viruses 1\u20103", "ORGANISM", 252, 277], ["PIVs 1\u20103", "ORGANISM", 279, 287], ["adenovirus", "ORGANISM", 290, 300], ["ADV", "ORGANISM", 302, 305], ["human", "ORGANISM", 312, 317], ["rhinovirus", "ORGANISM", 318, 328], ["human metapneumovirus", "ORGANISM", 471, 492], ["HMPV", "ORGANISM", 494, 498], ["human", "ORGANISM", 501, 506], ["bocavirus", "ORGANISM", 507, 516], ["HBoV", "ORGANISM", 518, 522], ["human", "ORGANISM", 529, 534], ["coronavirus", "ORGANISM", 535, 546], ["Mycoplasma pneumoniae", "ORGANISM", 577, 598], ["M. pneumoniae", "ORGANISM", 600, 613], ["lower", "ORGANISM_SUBDIVISION", 682, 687], ["respiratory tract", "ORGANISM_SUBDIVISION", 688, 705], ["children", "ORGANISM", 726, 734], ["respiratory viruses", "ORGANISM", 862, 881], ["M. pneumoniae", "ORGANISM", 886, 899], ["parainfluenza", "SPECIES", 252, 265], ["human", "SPECIES", 312, 317], ["rhinovirus", "SPECIES", 318, 328], ["human", "SPECIES", 471, 476], ["metapneumovirus", "SPECIES", 477, 492], ["human", "SPECIES", 501, 506], ["human", "SPECIES", 529, 534], ["coronavirus", "SPECIES", 535, 546], ["Mycoplasma pneumoniae", "SPECIES", 577, 598], ["M. pneumoniae", "SPECIES", 600, 613], ["children", "SPECIES", 726, 734], ["M. pneumoniae", "SPECIES", 886, 899], ["B viruses", "SPECIES", 190, 199], ["respiratory syncytial viruses", "SPECIES", 215, 244], ["RSV", "SPECIES", 246, 249], ["adenovirus", "SPECIES", 290, 300], ["ADV", "SPECIES", 302, 305], ["human rhinovirus", "SPECIES", 312, 328], ["HRV", "SPECIES", 330, 333], ["human metapneumovirus", "SPECIES", 471, 492], ["HMPV", "SPECIES", 494, 498], ["human bocavirus", "SPECIES", 501, 516], ["HBoV", "SPECIES", 518, 522], ["human coronavirus", "SPECIES", 529, 546], ["Mycoplasma pneumoniae", "SPECIES", 577, 598], ["M. pneumoniae", "SPECIES", 600, 613], ["M. pneumoniae", "SPECIES", 886, 899], ["viral pneumonia", "PROBLEM", 52, 67], ["The known causative viral pathogens", "PROBLEM", 86, 121], ["childhood pneumonia", "PROBLEM", 125, 144], ["seasonal influenza A and B viruses", "PROBLEM", 165, 199], ["IVA and IVB", "TREATMENT", 201, 212], ["respiratory syncytial viruses", "PROBLEM", 215, 244], ["RSV", "PROBLEM", 246, 249], ["parainfluenza viruses", "PROBLEM", 252, 273], ["PIVs", "TREATMENT", 279, 283], ["adenovirus", "PROBLEM", 290, 300], ["human rhinovirus", "PROBLEM", 312, 328], ["several novel respiratory viruses", "PROBLEM", 428, 461], ["human metapneumovirus (HMPV", "PROBLEM", 471, 498], ["human bocavirus (HBoV)", "PROBLEM", 501, 523], ["human coronavirus", "PROBLEM", 529, 546], ["Mycoplasma pneumoniae (M. pneumoniae", "PROBLEM", 577, 613], ["the pathogen", "PROBLEM", 638, 650], ["mild to severe lower respiratory tract infections", "PROBLEM", 667, 716], ["underlying disease", "PROBLEM", 767, 785], ["epidemics", "PROBLEM", 835, 844], ["respiratory viruses", "PROBLEM", 862, 881], ["M. pneumoniae", "PROBLEM", 886, 899], ["viral", "OBSERVATION_MODIFIER", 52, 57], ["pneumonia", "OBSERVATION", 58, 67], ["causative", "OBSERVATION_MODIFIER", 96, 105], ["viral", "OBSERVATION_MODIFIER", 106, 111], ["pathogens", "OBSERVATION", 112, 121], ["pneumonia", "OBSERVATION", 135, 144], ["seasonal influenza", "OBSERVATION", 165, 183], ["respiratory", "ANATOMY", 215, 226], ["syncytial viruses", "OBSERVATION", 227, 244], ["parainfluenza viruses", "OBSERVATION", 252, 273], ["respiratory viruses", "OBSERVATION", 442, 461], ["pneumoniae", "OBSERVATION", 588, 598], ["mild", "OBSERVATION_MODIFIER", 667, 671], ["severe", "OBSERVATION_MODIFIER", 675, 681], ["lower", "ANATOMY_MODIFIER", 682, 687], ["respiratory tract", "ANATOMY", 688, 705], ["infections", "OBSERVATION", 706, 716], ["disease", "OBSERVATION", 778, 785], ["substantial", "OBSERVATION_MODIFIER", 810, 821], ["respiratory viruses", "OBSERVATION", 862, 881], ["pneumoniae", "OBSERVATION", 889, 899]]], ["However, although there have been several reports that pathogen distribution varies by season and location, data on the etiology and epidemiology of pneumonia in children in developing countries are still insufficient, particularly in China.INTRODUCTIONThe purpose of the present work is to summarize the protocol of a multicenter, prospective cross\u2010sectional study investigating pneumonia in children <14 years of age, aiming to identify the etiological agents and related determinants involved.", [["pneumonia", "DISEASE", 149, 158], ["pneumonia", "DISEASE", 380, 389], ["children", "ORGANISM", 162, 170], ["children", "ORGANISM", 393, 401], ["children", "SPECIES", 162, 170], ["children", "SPECIES", 393, 401], ["pneumonia", "PROBLEM", 149, 158], ["prospective cross\u2010sectional study", "TEST", 332, 365], ["pneumonia", "PROBLEM", 380, 389], ["pathogen", "OBSERVATION_MODIFIER", 55, 63], ["distribution", "OBSERVATION_MODIFIER", 64, 76], ["pneumonia", "OBSERVATION", 149, 158], ["pneumonia", "OBSERVATION", 380, 389]]], ["Building upon the National Pediatric Research platform and Traditional Chinese Medicine Profession Special Purpose, established at the Affiliated Hospital to Liaoning University of Traditional Chinese Medicine in 2015, a 1\u2010year prospective study investigating the role of eight common viral respiratory pathogens and M. pneumoniae in the etiology of childhood CAP was conducted.", [["CAP", "DISEASE", 360, 363], ["M. pneumoniae", "ORGANISM", 317, 330], ["M. pneumoniae", "SPECIES", 317, 330], ["M. pneumoniae", "SPECIES", 317, 330], ["prospective study", "TEST", 228, 245], ["eight common viral respiratory pathogens", "PROBLEM", 272, 312], ["M. pneumoniae", "PROBLEM", 317, 330], ["childhood CAP", "PROBLEM", 350, 363], ["respiratory pathogens", "OBSERVATION", 291, 312], ["pneumoniae", "OBSERVATION", 320, 330]]], ["This report describes the associated epidemiologic characteristics of these pathogens.Patients ::: METHODSThe study population, which comprised children ranging in age from 6 months to 14 years, was selected according to protocol definitions and inclusion criteria.", [["Patients", "ORGANISM", 86, 94], ["children", "ORGANISM", 144, 152], ["Patients", "SPECIES", 86, 94], ["children", "SPECIES", 144, 152], ["these pathogens", "PROBLEM", 70, 85], ["pathogens", "OBSERVATION", 76, 85]]], ["Pneumonia cases were defined using the Child Community\u2010Acquired Pneumonia Guidelines (I, II) of the Chinese Medicine Association21, 22 as follows: (1) recent fever (>37.5\u00b0C), cough and/or dyspnea, tachypnea, and sputum; (2) fixed moderate or fine rales or dry rales during inspiration detected by lung auscultation; and (3) radiological confirmation of pneumonia was defined as the presence of consolidation (a dense or fluffy opacity with or without air bronchograms), other infiltrate (linear and patchy alveolar or interstitial densities), or pleural effusion.6 All radiologists were unaware of the patients\u2019 demographic and clinical information.", [["sputum", "ANATOMY", 212, 218], ["lung", "ANATOMY", 297, 301], ["alveolar", "ANATOMY", 506, 514], ["interstitial", "ANATOMY", 518, 530], ["pleural effusion", "ANATOMY", 546, 562], ["Pneumonia", "DISEASE", 0, 9], ["Pneumonia", "DISEASE", 64, 73], ["fever", "DISEASE", 158, 163], ["cough", "DISEASE", 175, 180], ["dyspnea", "DISEASE", 188, 195], ["tachypnea", "DISEASE", 197, 206], ["pneumonia", "DISEASE", 353, 362], ["opacity", "DISEASE", 427, 434], ["pleural effusion", "DISEASE", 546, 562], ["lung", "ORGAN", 297, 301], ["alveolar", "MULTI-TISSUE_STRUCTURE", 506, 514], ["patients", "ORGANISM", 602, 610], ["patients", "SPECIES", 602, 610], ["Pneumonia cases", "PROBLEM", 0, 15], ["Acquired Pneumonia", "PROBLEM", 55, 73], ["recent fever", "PROBLEM", 151, 163], ["cough", "PROBLEM", 175, 180], ["dyspnea", "PROBLEM", 188, 195], ["tachypnea", "PROBLEM", 197, 206], ["sputum", "PROBLEM", 212, 218], ["fixed moderate or fine rales", "PROBLEM", 224, 252], ["dry rales", "PROBLEM", 256, 265], ["lung auscultation", "TEST", 297, 314], ["radiological confirmation", "TEST", 324, 349], ["pneumonia", "PROBLEM", 353, 362], ["consolidation", "PROBLEM", 394, 407], ["a dense or fluffy opacity", "PROBLEM", 409, 434], ["air bronchograms", "PROBLEM", 451, 467], ["other infiltrate (linear and patchy alveolar or interstitial densities", "PROBLEM", 470, 540], ["pleural effusion", "PROBLEM", 546, 562], ["Pneumonia", "OBSERVATION", 64, 73], ["fever", "OBSERVATION", 158, 163], ["tachypnea", "OBSERVATION", 197, 206], ["moderate", "OBSERVATION_MODIFIER", 230, 238], ["fine", "OBSERVATION_MODIFIER", 242, 246], ["rales", "OBSERVATION", 247, 252], ["dry", "OBSERVATION_MODIFIER", 256, 259], ["rales", "OBSERVATION", 260, 265], ["lung", "ANATOMY", 297, 301], ["auscultation", "OBSERVATION", 302, 314], ["pneumonia", "OBSERVATION", 353, 362], ["consolidation", "OBSERVATION", 394, 407], ["dense", "OBSERVATION_MODIFIER", 411, 416], ["fluffy", "OBSERVATION_MODIFIER", 420, 426], ["opacity", "OBSERVATION", 427, 434], ["without", "UNCERTAINTY", 443, 450], ["air bronchograms", "OBSERVATION", 451, 467], ["infiltrate", "OBSERVATION", 476, 486], ["linear", "OBSERVATION_MODIFIER", 488, 494], ["patchy", "OBSERVATION_MODIFIER", 499, 505], ["alveolar", "ANATOMY_MODIFIER", 506, 514], ["interstitial", "ANATOMY_MODIFIER", 518, 530], ["densities", "OBSERVATION", 531, 540], ["pleural", "ANATOMY", 546, 553], ["effusion", "OBSERVATION", 554, 562]]], ["Chest X\u2010ray was performed and interpreted according to Cherian et al.23 Etiologic diagnosis was made by detection of positive respiratory antigens in nasopharyngeal secretions visualized by direct immunofluorescence.Samples and laboratory methods ::: METHODSNasopharyngeal secretions were collected by oropharyngeal swab for respiratory virus detection in the first 24 h of hospitalization, performed by trained clinical nurses.", [["respiratory", "ANATOMY", 126, 137], ["nasopharyngeal secretions", "ANATOMY", 150, 175], ["METHODSNasopharyngeal secretions", "ANATOMY", 251, 283], ["oropharyngeal swab", "ANATOMY", 302, 320], ["nasopharyngeal secretions", "ORGANISM_SUBSTANCE", 150, 175], ["secretions", "ORGANISM_SUBSTANCE", 273, 283], ["oropharyngeal swab", "MULTI-TISSUE_STRUCTURE", 302, 320], ["positive respiratory antigens", "PROTEIN", 117, 146], ["Chest X\u2010ray", "TEST", 0, 11], ["positive respiratory antigens in nasopharyngeal secretions", "PROBLEM", 117, 175], ["direct immunofluorescence", "TEST", 190, 215], ["METHODSNasopharyngeal secretions", "PROBLEM", 251, 283], ["oropharyngeal swab", "TEST", 302, 320], ["respiratory virus detection", "TEST", 325, 352], ["positive", "OBSERVATION_MODIFIER", 117, 125], ["respiratory antigens", "OBSERVATION", 126, 146], ["nasopharyngeal", "ANATOMY", 150, 164], ["secretions", "OBSERVATION", 165, 175], ["secretions", "OBSERVATION", 273, 283]]], ["After collection, each oropharyngeal swab was immediately placed into viral transport medium.", [["oropharyngeal swab", "ANATOMY", 23, 41], ["oropharyngeal swab", "ORGAN", 23, 41], ["collection", "PROBLEM", 6, 16], ["each oropharyngeal swab", "TEST", 18, 41], ["viral transport medium", "TREATMENT", 70, 92], ["oropharyngeal swab", "ANATOMY", 23, 41]]], ["The media were stored at 4\u00b0C, and the tubes were sent by cold chain within 48 h to the molecular laboratory of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine.Samples and laboratory methods ::: METHODSRespiratory virus antigens were detected by direct immunofluorescence assays (DFA) according to the reagent manufacturer's instructions (Xibei Biotechnology Co. Ltd., Shanghai, China).", [["tubes", "ANATOMY", 38, 43], ["tubes", "ORGANISM_SUBSTANCE", 38, 43], ["METHODSRespiratory virus antigens", "PROTEIN", 225, 258], ["METHODSRespiratory virus", "SPECIES", 225, 249], ["the tubes", "TREATMENT", 34, 43], ["Traditional Chinese Medicine", "TREATMENT", 161, 189], ["METHODSRespiratory virus antigens", "PROBLEM", 225, 258], ["direct immunofluorescence assays", "TEST", 276, 308], ["tubes", "OBSERVATION", 38, 43]]], ["The targeted pathogens were: RSV, ADV, IVA, IVB, PIVs1\u20103, and HMPV.", [["IVA", "CHEMICAL", 39, 42], ["RSV", "ORGANISM", 29, 32], ["PIVs1\u20103", "GENE_OR_GENE_PRODUCT", 49, 56], ["HMPV", "ORGANISM", 62, 66], ["RSV", "SPECIES", 29, 32], ["ADV", "SPECIES", 34, 37], ["HMPV", "SPECIES", 62, 66], ["RSV", "PROBLEM", 29, 32], ["IVA", "TREATMENT", 39, 42], ["IVB", "TREATMENT", 44, 47], ["PIVs1", "TREATMENT", 49, 54], ["HMPV", "PROBLEM", 62, 66], ["HMPV", "OBSERVATION", 62, 66]]], ["Specific IgM antibodies to M. pneumoniae were detected in serum samples of the patients (on admission) using a passive agglutination method according to the reagent manufacturer's instructions (RuiBiou Co. Ltd., Fuji, Japan).", [["serum samples", "ANATOMY", 58, 71], ["IgM", "GENE_OR_GENE_PRODUCT", 9, 12], ["M. pneumoniae", "ORGANISM", 27, 40], ["serum samples", "ORGANISM_SUBSTANCE", 58, 71], ["patients", "ORGANISM", 79, 87], ["IgM antibodies", "PROTEIN", 9, 23], ["M. pneumoniae", "SPECIES", 27, 40], ["patients", "SPECIES", 79, 87], ["M. pneumoniae", "SPECIES", 27, 40], ["Specific IgM antibodies", "TEST", 0, 23], ["M. pneumoniae", "PROBLEM", 27, 40], ["serum samples", "TEST", 58, 71], ["a passive agglutination method", "TREATMENT", 109, 139], ["pneumoniae", "OBSERVATION", 30, 40]]], ["The detection result was considered positive with a serum antibody titer \u22651:80.", [["serum", "ANATOMY", 52, 57], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["serum antibody", "PROTEIN", 52, 66], ["The detection", "TEST", 0, 13], ["a serum antibody titer", "TEST", 50, 72]]], ["IgM serology testing was chosen because, when compared with culture, serology, and PCR, it proved to be the most valuable tool for diagnosing M. pneumoniae infection.24", [["M. pneumoniae infection", "DISEASE", 142, 165], ["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["M. pneumoniae", "ORGANISM", 142, 155], ["IgM", "PROTEIN", 0, 3], ["M. pneumoniae", "SPECIES", 142, 155], ["M. pneumoniae", "SPECIES", 142, 155], ["IgM serology testing", "TEST", 0, 20], ["culture", "TEST", 60, 67], ["serology", "TEST", 69, 77], ["PCR", "TEST", 83, 86], ["M. pneumoniae infection", "PROBLEM", 142, 165], ["pneumoniae", "OBSERVATION", 145, 155]]]], "PMC7228214": [["INTRODUCTIONA recent outbreak of severe pneumonia was traced in the city Wuhan, Hubei province, China, causing 2761 deaths and at least 81109 cases (25 February 2020).", [["pneumonia", "DISEASE", 40, 49], ["deaths", "DISEASE", 116, 122], ["severe pneumonia", "PROBLEM", 33, 49], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["pneumonia", "OBSERVATION", 40, 49]]], ["The causative agent of the disease is a member of the Coronaviridae family, designed as severe acute respiratory syndrome coronavirus 2 isolate Wuhan\u2010Hu\u20101 (SARS\u2010CoV\u20102\u2010WH\u2010HU1: MN908947.3).1Reports indicated that SARS\u2010CoV\u20102 is closely related to three Chinese bat SARS\u2010like coronaviruses (Bat\u2010SL\u2010CoVs) forming a monophyletic cluster, denominated clade 2, within subgenus Sarbecovirus.1,2,3,4,5,6", [["acute respiratory syndrome coronavirus", "DISEASE", 95, 133], ["SARS", "DISEASE", 156, 160], ["SARS", "DISEASE", 211, 215], ["1,2,3,4,5,6", "CHEMICAL", 382, 393], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 216, 221], ["bat SARS\u2010like coronaviruses", "ORGANISM", 258, 285], ["Bat\u2010SL\u2010CoVs", "GENE_OR_GENE_PRODUCT", 287, 298], ["1,2,3,4,5,6", "SIMPLE_CHEMICAL", 382, 393], ["CoV\u20102", "DNA", 216, 221], ["severe acute respiratory syndrome coronavirus", "SPECIES", 88, 133], ["Wuhan\u2010Hu\u20101 (SARS\u2010CoV", "SPECIES", 144, 164], ["Chinese bat SARS\u2010like coronaviruses", "SPECIES", 250, 285], ["the disease", "PROBLEM", 23, 34], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 88, 133], ["SARS\u2010CoV\u20102", "PROBLEM", 211, 221], ["coronaviruses (Bat\u2010SL\u2010CoVs)", "PROBLEM", 272, 299], ["a monophyletic cluster", "PROBLEM", 308, 330], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["respiratory syndrome", "OBSERVATION", 101, 121]]]], "PMC4150440": [], "a15de79245e4f45b00d9cf099f6af1ba656b2c42": [["IntroductionCardiac arrhythmia, defined as an abnormal heart rhythm, is a common problem in cardiology, and can range from benign to potentially life-threatening rhythm type [1, 2] .IntroductionOfficial (Closed) -Non Sensitive Therefore, early detection of arrhythmia is an important clinical task that can save lives.", [["heart", "ANATOMY", 55, 60], ["IntroductionCardiac arrhythmia", "DISEASE", 0, 30], ["abnormal heart rhythm", "DISEASE", 46, 67], ["arrhythmia", "DISEASE", 257, 267], ["heart", "ORGAN", 55, 60], ["IntroductionCardiac arrhythmia", "PROBLEM", 0, 30], ["an abnormal heart rhythm", "PROBLEM", 43, 67], ["arrhythmia", "PROBLEM", 257, 267], ["arrhythmia", "OBSERVATION", 20, 30], ["heart", "ANATOMY", 55, 60], ["arrhythmia", "OBSERVATION", 257, 267]]], ["The commonest method to detect cardiac arrhythmia uses the electrocardiogram (ECG), which measures the electrical activity of the heart.", [["cardiac", "ANATOMY", 31, 38], ["heart", "ANATOMY", 130, 135], ["cardiac arrhythmia", "DISEASE", 31, 49], ["cardiac", "ORGAN", 31, 38], ["heart", "ORGAN", 130, 135], ["cardiac arrhythmia", "PROBLEM", 31, 49], ["the electrocardiogram", "TEST", 55, 76], ["ECG", "TEST", 78, 81], ["cardiac", "ANATOMY", 31, 38], ["arrhythmia", "OBSERVATION", 39, 49], ["electrical activity", "OBSERVATION", 103, 122], ["heart", "ANATOMY", 130, 135]]], ["In general, the ECG records include a long duration (i.e., several hours or days) of heart activity samples, as needed for detecting and analyzing arrhythmia [3] .", [["heart", "ANATOMY", 85, 90], ["samples", "ANATOMY", 100, 107], ["arrhythmia", "DISEASE", 147, 157], ["heart", "ORGAN", 85, 90], ["the ECG records", "TEST", 12, 27], ["heart activity samples", "TEST", 85, 107], ["analyzing arrhythmia", "PROBLEM", 137, 157], ["heart", "ANATOMY", 85, 90]]], ["Therefore, enhanced fully automated computer-aided diagnosis systems (CADs) with high accuracy can be feasible and even essential solutions to assist clinical experts during the analysis process [6, 7] .IntroductionMachine learning-based approaches are frequently utilized to recognize arrhythmia [8] [9] [10] [11] [12] .IntroductionPre-processing, feature extraction, and classification tasks are the main steps involved in these approaches [13] .", [["arrhythmia", "DISEASE", 286, 296], ["[8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 297, 319], ["the analysis process", "TEST", 174, 194], ["IntroductionMachine learning", "TREATMENT", 203, 231], ["arrhythmia", "PROBLEM", 286, 296], ["feature extraction", "TREATMENT", 349, 367]]], ["The researchers choose both some clinical features (i.e., P, QRS, T wave amplitude and duration, etc.) and arbitrary features to meet this aim.", [["QRS, T wave amplitude and duration", "PROBLEM", 61, 95], ["arbitrary features", "PROBLEM", 107, 125]]], ["In the feature extraction phase, useful morphological [14, 15] , temporal [14, [16] [17] [18] [19] , frequency-based [20] [21] [22] and/or transform-based [23] [24] [25] [26] [27] [28] features from ECG waveforms are obtained to improve the distinction between samples.", [["samples", "ANATOMY", 261, 268], ["[14, [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 74, 98], ["[20] [21] [22]", "SIMPLE_CHEMICAL", 117, 131], ["[23] [24] [25] [26] [27] [28]", "SIMPLE_CHEMICAL", 155, 184], ["samples", "CANCER", 261, 268], ["ECG waveforms", "TEST", 199, 212]]], ["In recent years, deep learning [32, 33] has become a popular subfield of artificial intelligence.", [["deep", "ANATOMY_MODIFIER", 17, 21], ["artificial intelligence", "OBSERVATION", 73, 96]]], ["The deep learning models usually have an end-toend structure.", [["deep", "ANATOMY_MODIFIER", 4, 8]]], ["This architectural structure enables one to perform feature extraction and classification steps together [34] .", [["feature extraction", "TREATMENT", 52, 70]]], ["It has been effectively used in medical applications such as brain image analysis [35] [36] [37] [38] , histopathological images [39] [40] [41] , and brain electroencephalogram (EEG) signal analyses [42] [43] [44] [45] .", [["brain", "ANATOMY", 61, 66], ["brain", "ANATOMY", 150, 155], ["brain", "ORGAN", 61, 66], ["brain", "ORGAN", 150, 155], ["brain image analysis", "TEST", 61, 81], ["histopathological images", "TEST", 104, 128], ["brain electroencephalogram", "TEST", 150, 176], ["signal analyses", "TEST", 183, 198]]], ["It has also been adopted for the detection of coronavirus (COVID-19) patients [46] [47] [48] [49] [50] [51] .IntroductionDeep learning has been the preferred mode of ECG classification over the last few years [4, 31, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] .", [["4, 31, [52] [53] [54] [55] [56] [57] [58] [59] [60]", "CHEMICAL", 210, 261], ["coronavirus", "ORGANISM", 46, 57], ["patients", "ORGANISM", 69, 77], ["[47] [48] [49] [50", "SIMPLE_CHEMICAL", 83, 101], ["[52] [53] [54] [55] [56] [57] [58] [59] [60] [61]", "SIMPLE_CHEMICAL", 217, 266], ["patients", "SPECIES", 69, 77], ["the detection", "TEST", 29, 42], ["coronavirus (COVID", "TEST", 46, 64], ["ECG classification", "TEST", 166, 184]]], ["One-dimensional convolutional neural networks (1D-CNN) have become popular to classify ECG records because of their one-dimension structure.", [["convolutional neural networks", "ANATOMY", 16, 45], ["neural networks", "MULTI-TISSUE_STRUCTURE", 30, 45], ["ECG records", "TEST", 87, 98], ["neural networks", "OBSERVATION", 30, 45]]], ["In 2015, Kiranyaz et. al. [55] proposed a 1D convolutional neural network (1D-CNN) model for patient-specific ECG classification.", [["neural network", "MULTI-TISSUE_STRUCTURE", 59, 73], ["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["a 1D convolutional neural network", "TREATMENT", 40, 73]]], ["They obtained an accuracy of 94.03% from original signals using an augmentation technique.", [["an accuracy", "TEST", 14, 25], ["an augmentation technique", "TREATMENT", 64, 89]]], ["Hannun et al. [56] proposed a CNN model that consists of 33 convolutional layers to classify 12 rhythm categories.", [["a CNN model", "TEST", 28, 39]]], ["They based their work on a large ECG dataset containing Official (Closed) -Non Sensitive 91,232 records from 53,549 patients.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["a large ECG dataset", "TEST", 25, 44]]], ["Li et al. [57] presented a generic CNN for patientspecific ECG classification.", [["Li", "CHEMICAL", 0, 2]]], ["Oh et al. [58] suggested a modified U-net architecture to diagnose beat wise arrhythmia.", [["arrhythmia", "DISEASE", 77, 87], ["a modified U-net architecture", "TREATMENT", 25, 54], ["arrhythmia", "PROBLEM", 77, 87]]], ["Li et al. [59] developed a 31-layer 1D residual CNN model to identify five different types of heartbeats.", [["Li", "CHEMICAL", 0, 2], ["a 31-layer 1D residual CNN model", "PROBLEM", 25, 57]]], ["Li et al. [31] recommended a customized CNN model to classify patient-specific heartbeat using 44 records.", [["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["a customized CNN model", "TREATMENT", 27, 49]]], ["Yildirim et al. [60] applied a CNN model for classification of 17 cardiac arrhythmias using long-duration ECG signals.", [["cardiac", "ANATOMY", 66, 73], ["cardiac arrhythmias", "DISEASE", 66, 85], ["a CNN model", "TREATMENT", 29, 40], ["17 cardiac arrhythmias", "PROBLEM", 63, 85], ["long-duration ECG signals", "TEST", 92, 117], ["cardiac", "ANATOMY", 66, 73], ["arrhythmias", "OBSERVATION", 74, 85]]], ["Sharker et al. [61] proposed an end-to-end deep learning model to classify 15 ECG classes.IntroductionAnother deep learning algorithm for ECG analysis is long short-term memory networks (LSTM), known as sequence learning.", [["memory networks", "MULTI-TISSUE_STRUCTURE", 170, 185], ["long short-term memory networks", "DNA", 154, 185], ["ECG classes", "TEST", 78, 89], ["ECG analysis", "TEST", 138, 150]]], ["LSTM is a practical approach to analyze time-series data [62] .", [["series data", "TEST", 45, 56]]], ["In the last decade, the LSTM algorithm has been employed for arrhythmia detection [30, [63] [64] [65] [66] [67] [68] [70] [71] [72] [73] .", [["arrhythmia", "DISEASE", 61, 71], ["[30, [63] [64] [65] [66] [67] [68] [70] [71] [72] [73]", "CHEMICAL", 82, 136], ["[63] [64] [65] [66] [67] [68] [70] [71] [72] [73]", "SIMPLE_CHEMICAL", 87, 136], ["the LSTM algorithm", "TEST", 20, 38], ["arrhythmia detection", "TEST", 61, 81]]], ["Yildirim [65] proposed a wavelet sequence-based LSTM model to classify ECG signals.", [["Yildirim", "CHEMICAL", 0, 8], ["LSTM model", "CELL_LINE", 48, 58], ["a wavelet sequence", "TREATMENT", 23, 41], ["ECG signals", "TEST", 71, 82]]], ["Chang et al. [66] employed a bidirectional LSTM model to classify 12 common heart rhythms on 12-lead ECG signals collected from 38,899 patients.", [["heart", "ANATOMY", 76, 81], ["heart", "ORGAN", 76, 81], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["a bidirectional LSTM model", "TREATMENT", 27, 53], ["lead ECG signals", "TEST", 96, 112], ["heart", "ANATOMY", 76, 81]]], ["Gao et al. [30] used an LSTM model with focal loss (FL) to classify eight different heartbeats.", [["focal loss", "DISEASE", 40, 50], ["an LSTM model", "TREATMENT", 21, 34], ["focal loss (FL)", "PROBLEM", 40, 55], ["focal", "OBSERVATION_MODIFIER", 40, 45]]], ["The performance of deep models tends to improve with more training data [32] .", [["deep", "ANATOMY_MODIFIER", 19, 23]]], ["The most widely used public database for arrhythmia studies is the MIT-BIH Arrhythmia Database [76] collected 40 years ago [77] .", [["arrhythmia", "DISEASE", 41, 51], ["Arrhythmia", "DISEASE", 75, 85], ["arrhythmia studies", "TEST", 41, 59], ["Arrhythmia", "PROBLEM", 75, 85]]], ["Therefore, the construction of new large public datasets plays a vital role for studies on arrhythmia.", [["arrhythmia", "DISEASE", 91, 101], ["arrhythmia", "PROBLEM", 91, 101], ["new", "OBSERVATION_MODIFIER", 31, 34], ["large", "OBSERVATION_MODIFIER", 35, 40]]], ["As described herein, we used one of the largest public ECG datasets to detect rhythm classes [78] .", [["rhythm classes", "PROBLEM", 78, 92]]], ["The database includes 12-lead ECG signals collected from more than 10,000 individual subjects.", [["The database", "TEST", 0, 12], ["lead ECG signals", "TEST", 25, 41]]], ["We preferred to use the representation and sequence learning structure together because of their salutary performance on both ECG [52, 67, 68, 72] and EEG signals [45] .", [["both ECG", "TEST", 121, 129], ["EEG signals", "TEST", 151, 162]]], ["The novelty of this paper can be summarized as follows: a useful single DNN model has been constructed to detect multiple rhythm classes on 12-lead signals.", [["multiple rhythm classes", "PROBLEM", 113, 136]]], ["The experiments are performed on one of the recent largest new ECG datasets, including more than 10,000 subjects.", [["largest", "OBSERVATION_MODIFIER", 51, 58]]], ["To the best of our knowledge, this is the first deep model study to classify rhythms using this ECG dataset.", [["this ECG dataset", "TEST", 91, 107]]], ["Additionally, the training and testing subjects were different, so that there is no overlap between the train and the test sets.Materials and MethodsIn this paper, we used both representation and sequence learning to detect heart rhythms and conducted the experiments in a large ECG database.", [["heart", "ANATOMY", 224, 229], ["heart", "ORGAN", 224, 229], ["the training and testing subjects", "TEST", 14, 47], ["the test sets", "TEST", 114, 127], ["Methods", "TREATMENT", 142, 149], ["heart rhythms", "TEST", 224, 237], ["a large ECG database", "TEST", 271, 291], ["heart", "ANATOMY", 224, 229]]], ["The database had been recently published for arrhythmia research and encompasses more than 10,000 individual subject ECG records.", [["arrhythmia", "DISEASE", 45, 55], ["arrhythmia", "PROBLEM", 45, 55]]], ["In Fig. 1 , a block representation of the materials and methods is given for the study.The Proposed DNN ModelWe designed a new deep neural network model to classify rhythms automatically.", [["neural network", "ANATOMY", 132, 146], ["neural network", "MULTI-TISSUE_STRUCTURE", 132, 146], ["DNN ModelWe", "CELL_LINE", 100, 111], ["a block representation of the materials", "TREATMENT", 12, 51], ["methods", "TREATMENT", 56, 63], ["the study", "TEST", 77, 86], ["a new deep neural network model", "TREATMENT", 121, 152], ["new", "OBSERVATION_MODIFIER", 123, 126], ["deep neural network", "OBSERVATION", 127, 146]]], ["In Fig.2 , a block representation of the proposed DNN model is given.", [["DNN", "CANCER", 50, 53], ["Fig.2", "CELL_LINE", 3, 8], ["a block representation", "TREATMENT", 11, 33], ["the proposed DNN model", "TREATMENT", 37, 59]]], ["We constructed the proposed deep learning model using different layer combinations.", [["the proposed deep learning model", "TREATMENT", 15, 47], ["different layer combinations", "TREATMENT", 54, 82], ["deep", "ANATOMY_MODIFIER", 28, 32]]], ["We preferred a one-dimensional convolutional neural network (1D-CNN) due to the one-dimensional structure of ECG signals.", [["neural network", "MULTI-TISSUE_STRUCTURE", 45, 59]]], ["One-dimensional-CNN models have an excellent ability to learn distinguishing hierarchical features from the raw inputs when applying a 1D convolution.", [["a 1D convolution", "TREATMENT", 133, 149], ["excellent", "OBSERVATION_MODIFIER", 35, 44]]], ["This procedure is also known as representation learning [45] .", [["This procedure", "TREATMENT", 0, 14]]], ["The model learns low-level features at beginning layers and high-level features through the consecutive layers hierarchically.", [["The model learns low-level features", "PROBLEM", 0, 35], ["high-level features", "PROBLEM", 60, 79], ["low", "OBSERVATION_MODIFIER", 17, 20], ["layers", "OBSERVATION_MODIFIER", 49, 55], ["high", "OBSERVATION_MODIFIER", 60, 64]]], ["After the 1D convolution step, many feature matrices termed feature maps emerge.", [["the 1D convolution step", "TREATMENT", 6, 29]]], ["These maps are subsampled by the max-pooling layers to reduce computational cost.", [["These maps", "TEST", 0, 10], ["the max-pooling layers", "TREATMENT", 29, 51], ["computational cost", "OBSERVATION", 62, 80]]], ["A tedious task is to determine the correct parameters, such as the number of filters, kernel size, and strides.", [["A tedious task", "TEST", 0, 14], ["size", "OBSERVATION_MODIFIER", 93, 97]]], ["We used both our previous experience on the long duration ECG signals [60] and brute force techniques to adjust these parameters.", [["the long duration ECG signals", "TEST", 40, 69], ["brute force techniques", "TREATMENT", 79, 101], ["these parameters", "TEST", 112, 128]]], ["For the number of filters, experiments were made based upon exponents of two, in the range from 16 to 1024.", [["filters", "OBSERVATION", 18, 25]]], ["Performance observations were made by selecting values from a smaller search space such as 2, 3, 5, 7, 9 and 13 for kernel sizes.The Proposed DNN ModelSince the length of the input signal is long, 21 kernels are used in the first layer and 11 strides are used to reduce the computational cost.", [["2, 3, 5, 7, 9 and 13", "DNA", 91, 111], ["DNN", "DNA", 142, 145], ["smaller", "OBSERVATION_MODIFIER", 62, 69], ["sizes", "OBSERVATION_MODIFIER", 123, 128], ["length", "OBSERVATION_MODIFIER", 161, 167], ["long", "OBSERVATION_MODIFIER", 191, 195], ["layer", "OBSERVATION_MODIFIER", 230, 235], ["computational cost", "OBSERVATION", 274, 292]]], ["These processes can be solved with a satisfactory optimization approach and hardware with high computing power.", [["a satisfactory optimization approach", "TREATMENT", 35, 71], ["hardware", "TREATMENT", 76, 84]]], ["In the proposed model, the first convolution layer had 64 filters with 21 kernel size that was applied to the raw input signals using an eleven movement amount (strides).", [["64 filters", "TREATMENT", 55, 65], ["21 kernel size", "TREATMENT", 71, 85], ["layer", "OBSERVATION_MODIFIER", 45, 50], ["64 filters", "OBSERVATION", 55, 65], ["size", "OBSERVATION_MODIFIER", 81, 85]]], ["The feature maps obtained from this step were sub-sampled in a max-pooling layer.", [["The feature maps", "TEST", 0, 16]]], ["The proposed model consisted of six different convolution layers and four max-pooling layers.", [["six different convolution layers", "PROBLEM", 32, 64], ["six", "OBSERVATION_MODIFIER", 32, 35], ["different", "OBSERVATION_MODIFIER", 36, 45], ["convolution", "OBSERVATION_MODIFIER", 46, 57], ["layers", "OBSERVATION_MODIFIER", 58, 64], ["four", "OBSERVATION_MODIFIER", 69, 73], ["max-", "OBSERVATION_MODIFIER", 74, 78], ["pooling", "OBSERVATION_MODIFIER", 78, 85], ["layers", "OBSERVATION_MODIFIER", 86, 92]]], ["We used two batch normalization layers to normalize the data.", [["two batch normalization layers", "TREATMENT", 8, 38]]], ["Two dropout layers were placed at different positions of the model to avoid the overfitting problem.", [["Two dropout layers", "TREATMENT", 0, 18], ["the overfitting problem", "PROBLEM", 76, 99], ["dropout", "OBSERVATION_MODIFIER", 4, 11], ["layers", "OBSERVATION_MODIFIER", 12, 18], ["overfitting", "OBSERVATION", 80, 91]]], ["A Leaky-ReLU layer with 0.1 alpha value was used at the beginning layers.", [["A Leaky-ReLU layer", "PROBLEM", 0, 18], ["Leaky", "OBSERVATION", 2, 7], ["ReLU", "OBSERVATION_MODIFIER", 8, 12], ["layer", "OBSERVATION_MODIFIER", 13, 18]]], ["All layers mentioned so far were used for representation learning.", [["layers", "OBSERVATION_MODIFIER", 4, 10]]], ["In the model, an LSTM block was used for sequence learning.", [["LSTM block", "DNA", 17, 27], ["an LSTM block", "TREATMENT", 14, 27]]], ["Some studies on 1D signals such as EEG and ECG [52, 67, 68, 72] show that the combination of representation and sequence learning can yield a higher performance than by using representation learning alone.", [["Some studies", "TEST", 0, 12], ["1D signals", "TEST", 16, 26], ["EEG", "TEST", 35, 38], ["ECG", "TEST", 43, 46]]], ["According to this information, we used a 128 unit LSTM block at the end of the representation learning layers.", [["128 unit LSTM block", "DNA", 41, 60], ["a 128 unit LSTM block", "TREATMENT", 39, 60]]], ["The database includes a large number of individual subjects -more than 10,000 -with 12-lead ECG signals sampled at a higher than usual sampling rate of 500 Hz.", [["ECG signals", "TEST", 92, 103], ["large", "OBSERVATION_MODIFIER", 24, 29], ["number", "OBSERVATION_MODIFIER", 30, 36]]], ["In this database, there are 11 heart rhythms and 56 types of cardiovascular conditions labelled by professional physicians.", [["heart", "ANATOMY", 31, 36], ["cardiovascular", "ANATOMY", 61, 75], ["heart rhythms", "DISEASE", 31, 44], ["heart", "ORGAN", 31, 36], ["11 heart rhythms", "PROBLEM", 28, 44], ["heart", "ANATOMY", 31, 36]]], ["The database comprises 10,646 patients, and 12-lead ECGs records were acquired over 10 seconds.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["The Butterworth low pass filter [79] , the local polynomial regression smoother (LOESS) [80] , and Non-Local Means (NLM) techniques [81] had been used sequentially to process raw ECG records.", [["The Butterworth low pass filter", "TREATMENT", 0, 31], ["the local polynomial regression smoother", "TREATMENT", 39, 79]]], ["Signal components with a frequency above 50 Hz and the effects of baseline wandering were removed using these methods.", [["Signal components", "PROBLEM", 0, 17], ["baseline wandering", "PROBLEM", 66, 84], ["these methods", "TREATMENT", 104, 117], ["components", "OBSERVATION_MODIFIER", 7, 17]]], ["In Fig. 3 , the preprocess step is shown with a signal sample and frequency spectrums.", [["the preprocess step", "TEST", 12, 31], ["a signal sample", "TEST", 46, 61]]], ["Since some ECG recordings contain only zeros, and some channel values were missing, we used a total of 10,588 topics from this database.", [["some ECG recordings", "TEST", 6, 25], ["zeros", "PROBLEM", 39, 44], ["some channel values", "PROBLEM", 50, 69]]], ["Table 2 contains some numerical information about the recordings used, and Fig.4 depicts a distribution rate graph of rhythm classes across the database.", [["Fig.4", "PROTEIN", 75, 80]]], ["Some numerical information about the ECG records used.Number of SamplesAge, Mean \u00b1 StdExperimental ResultsIn this section, we present experimental results to detect rhythm classes on 10-second ECG signals.", [["the ECG records", "TEST", 33, 48], ["SamplesAge", "TEST", 64, 74], ["Mean", "TEST", 76, 80]]], ["We used 11 rhythms with two scenarios, and seven and four categories.Experimental SetupsIn this study, two different experiments were performed on the dataset.", [["this study", "TEST", 91, 101]]], ["Also, 12-lead ECG signals from different subjects were used separately for analysis and performance evaluations.", [["lead ECG signals", "TEST", 9, 25], ["analysis", "TEST", 75, 83], ["performance evaluations", "TEST", 88, 111]]], ["We have used an inter-patient scheme during the experiments.", [["an inter-patient scheme", "TREATMENT", 13, 36]]], ["Only a single efficient DNN model was used for all experiments.", [["DNN model", "CELL_LINE", 24, 33], ["a single efficient DNN model", "TREATMENT", 5, 33]]], ["The hyper-parameters of the DNN model were not altered during training.Experimental SetupsThe standard hyper-parameters of the model were set as a learning value of 0.002, and batch size 128.", [["the DNN model", "TREATMENT", 24, 37], ["Experimental Setups", "TREATMENT", 71, 90], ["batch size", "TEST", 176, 186], ["not", "UNCERTAINTY", 43, 46], ["altered", "OBSERVATION_MODIFIER", 47, 54]]], ["We categorically used the cross-entropy loss function and Adam optimizer to adjust the weights of the model [82] .", [["the cross-entropy loss function", "TREATMENT", 22, 53], ["Adam optimizer", "TREATMENT", 58, 72]]], ["All experiments were performed on a computer with specifications of Intel Core i7-7700HQ 2.81GHz CPU, 16GB memory, and 8 GB NVIDIA GeForce GTX 1070 graphics card.", [["GTX", "CHEMICAL", 139, 142]]], ["The DNN model was constructed using the Keras (v 2.3.1) deep learning library [83] and the TensorFlow (v. 1.14.0) framework.Experimental SetupsAnother important step is preparing train, validation, and test sets for the implementation of the model.", [["the Keras (v", "TREATMENT", 36, 48]]], ["There are two standard methods for this task, cross-validation and random splitting.", [["this task", "TEST", 35, 44], ["cross-validation", "TEST", 46, 62]]], ["In general, per subject evaluation of the models can provide more reliable results.Experimental SetupsEach subject in this database has only one unique record.", [["subject evaluation", "TEST", 16, 34]]], ["The large size of the ECG dataset renders it suitable for random splitting.", [["the ECG dataset", "TEST", 18, 33], ["random splitting", "PROBLEM", 58, 74], ["large", "OBSERVATION_MODIFIER", 4, 9], ["size", "OBSERVATION_MODIFIER", 10, 14]]], ["The dataset randomly divided into training, validation, and test sets as 80%, 10%, and 10%, respectively.", [["validation", "TEST", 44, 54], ["test sets", "TEST", 60, 69]]], ["We used the same records for training, validation, and testing for the experiments to compare the performances consistently.", [["validation", "TEST", 39, 49], ["testing", "TEST", 55, 62]]], ["We evaluated the performance of the model on the test sets using standard evaluation metrics, such as accuracy, specificity, sensitivity, precision, and F-score.", [["the test sets", "TEST", 45, 58], ["standard evaluation metrics", "TEST", 65, 92], ["accuracy", "TEST", 102, 110]]], ["The calculations of these criteria, according to distribution of true positive (TP), true negative (TN), false positive (FP) and false negative (FN) samples, are given as follows:Accuracy=(TP+TN)/Total(1)Specificity=TN/(FP+FN)Precision=TP/(TP+FP)Specificity=TN/(FP+FN)Recall=TP/(TP+FN)Reduced Rhythm ClassesIn this section, we used the DNN model on seven rhythm classes. sinus atrium to atrial wandering rhythm, we eliminated these classes during the experiment.", [["sinus atrium", "ANATOMY", 371, 383], ["atrial", "ANATOMY", 387, 393], ["TP", "GENE_OR_GENE_PRODUCT", 80, 82], ["sinus atrium", "MULTI-TISSUE_STRUCTURE", 371, 383], ["atrial", "MULTI-TISSUE_STRUCTURE", 387, 393], ["TN", "PROTEIN", 100, 102], ["FN", "PROTEIN", 145, 147], ["TN", "PROTEIN", 192, 194], ["TN", "PROTEIN", 216, 218], ["FN", "PROTEIN", 223, 225], ["TN", "PROTEIN", 258, 260], ["FP", "PROTEIN", 262, 264], ["FN", "PROTEIN", 265, 267], ["TP", "PROTEIN", 275, 277], ["TP", "PROTEIN", 279, 281], ["FN", "PROTEIN", 282, 284], ["these criteria", "TEST", 20, 34], ["true positive (TP)", "PROBLEM", 65, 83], ["FP", "TEST", 121, 123], ["Accuracy", "TEST", 179, 187], ["TP", "TEST", 189, 191], ["TN", "TEST", 192, 194], ["Specificity", "TEST", 204, 215], ["TN", "TEST", 216, 218], ["FP", "TEST", 220, 222], ["FN", "TEST", 223, 225], ["Precision", "TEST", 226, 235], ["TP", "TEST", 236, 238], ["TP", "TEST", 240, 242], ["FP", "TEST", 243, 245], ["Specificity", "TEST", 246, 257], ["TN", "TEST", 258, 260], ["FP", "TEST", 262, 264], ["FN", "TEST", 265, 267], ["Recall", "TEST", 268, 274], ["TP", "TEST", 275, 277], ["TP", "TEST", 279, 281], ["Reduced Rhythm Classes", "PROBLEM", 285, 307], ["the DNN model", "TREATMENT", 332, 345], ["sinus atrium", "PROBLEM", 371, 383], ["atrial wandering rhythm", "PROBLEM", 387, 410], ["atrium", "ANATOMY", 377, 383], ["atrial", "ANATOMY", 387, 393], ["wandering rhythm", "OBSERVATION", 394, 410]]], ["In Table 3 , the used dataset includes seven rhythms and is given here with detail.Reduced Rhythm ClassesOfficial (Closed) -Non Sensitive Firstly, we divided the reduced dataset into training, validation, and testing sets as 80%, 10%, and 10%, respectively.", [["Reduced Rhythm", "PROBLEM", 83, 97], ["validation", "TEST", 193, 203], ["testing sets", "TEST", 209, 221]]], ["It is seen that the data distributions used in this scenario are After the training process, the performance of the DNN model was tested on the unseen test sets.", [["the training process", "TREATMENT", 71, 91], ["the DNN model", "TEST", 112, 125], ["the unseen test sets", "TEST", 140, 160]]], ["Deep learning models use validation samples for adjusting network parameters.", [["validation samples", "TEST", 25, 43]]], ["Thus, reliable performance measurements could be obtained from the unseen test sets.", [["reliable performance measurements", "TEST", 6, 39], ["the unseen test sets", "TEST", 63, 83]]], ["The trained model was applied to the test records and yielded promising results on unseen data.", [["the test records", "TEST", 33, 49], ["unseen data", "TEST", 83, 94]]], ["In Figure 7 , we showed four confusion matrices obtained during the test process.", [["confusion", "DISEASE", 29, 38], ["four confusion matrices", "PROBLEM", 24, 47], ["the test process", "TEST", 64, 80]]], ["The confusion matrix has an essential role in the evaluation of the performance of a model.", [["confusion", "DISEASE", 4, 13], ["matrix", "CELLULAR_COMPONENT", 14, 20], ["The confusion matrix", "PROBLEM", 0, 20], ["the evaluation", "TEST", 46, 60], ["confusion matrix", "OBSERVATION", 4, 20]]], ["In Fig. 7 For further performance evaluation, we examined the values of the test results for each rhythm class compared with Lead-II input, so as to ascertain which classes yielded a weak or strong performance by the DNN model.", [["further performance evaluation", "TEST", 14, 44], ["the test", "TEST", 72, 80]]], ["We chose the Lead-II signal for this purpose, due to both its high accuracy values, and the fact that it is commonly used in many ECG analysis studies.", [["many ECG analysis studies", "TEST", 125, 150]]], ["In Table 5 , some standard performance measurements of rhythm classes on the test subjects are given. for this can be the low number of data in this class.", [["the test subjects", "TEST", 73, 90]]], ["A similar problem was also observed between the SI and SR classes.", [["similar", "OBSERVATION_MODIFIER", 2, 9], ["problem", "OBSERVATION", 10, 17]]], ["On the other hand, the model was able to distinguish sinus bradycardia (SB) signals from other classes, with a 99.04% accuracy performance.", [["sinus", "ANATOMY", 53, 58], ["sinus bradycardia", "DISEASE", 53, 70], ["sinus bradycardia", "PROBLEM", 53, 70], ["bradycardia", "OBSERVATION", 59, 70]]], ["Some examples of AF and SR signals that the proposed model incorrectly predicted (Actual: original class, predicted: detected class by the model).Merged Rhythm ClassesIn the previous experiments, the DNN model produced some weak class performances due to similarity, e.g. the AF, AFIB, SR, and SI classes yielded low-performance values.", [["AF", "DISEASE", 276, 278], ["AF", "PROBLEM", 17, 19], ["some weak class performances", "PROBLEM", 219, 247], ["the AF", "PROBLEM", 272, 278], ["AFIB", "PROBLEM", 280, 284], ["SR", "PROBLEM", 286, 288], ["AF", "OBSERVATION", 17, 19]]], ["Also, in the dataset, several classes had fewer samples, such as AVNRT, AVRT, and SAAWR.", [["samples", "ANATOMY", 48, 55], ["AVNRT", "PROBLEM", 65, 70], ["AVRT", "PROBLEM", 72, 76], ["SAAWR", "PROBLEM", 82, 87]]], ["To overcome this, we merged 11 rhythms into four classes as AFIB, grouped supraventricular tachycardia (GSVT), SB, and SR, according to the original dataset article [78] .", [["supraventricular", "ANATOMY", 74, 90], ["supraventricular tachycardia", "DISEASE", 74, 102], ["GSVT", "DISEASE", 104, 108], ["AFIB", "PROBLEM", 60, 64], ["grouped supraventricular tachycardia", "PROBLEM", 66, 102], ["SB", "PROBLEM", 111, 113], ["supraventricular tachycardia", "OBSERVATION", 74, 102]]], ["In this experiment, we applied the DNN model on these merged rhythm classes.", [["the DNN model", "TREATMENT", 31, 44]]], ["We divided the merged dataset into training, validation and testing sets as 80%, 10%, and 10%, respectively.", [["validation", "TEST", 45, 55], ["testing sets", "TEST", 60, 72]]], ["The same hyper-parameters from previous experiments were used in this experiment.", [["previous experiments", "TREATMENT", 31, 51], ["hyper", "OBSERVATION", 9, 14]]], ["In Fig. 10 , accuracy and loss graphs for each lead are given during the training step.", [["accuracy", "TEST", 13, 21]]], ["There was no overfitting or underfitting problem.", [["overfitting", "PROBLEM", 13, 24], ["underfitting problem", "PROBLEM", 28, 48], ["no", "UNCERTAINTY", 10, 12], ["overfitting", "OBSERVATION", 13, 24]]], ["The trained model has been applied to the unseen test records.Merged Rhythm ClassesWe present all confusion matrices for each lead signal in Fig. 11 .", [["confusion", "DISEASE", 98, 107], ["Rhythm ClassesWe", "DNA", 69, 85], ["each lead signal in Fig", "PROBLEM", 121, 144]]], ["Table 7 , the performance metrics on the test sets are given in detail.Merged Rhythm ClassesOfficial (Closed) -Non Sensitive The best overall performances were obtained from the Lead-II input with 95.43% sensitivity, 98.71% specificity, 95.78% precision, 95.57% F-score, and 96.13% accuracy.", [["the test sets", "TEST", 37, 50], ["sensitivity", "TEST", 204, 215], ["specificity", "TEST", 224, 235], ["precision", "TEST", 244, 253]]], ["The lowest sensitivity performance, which emerged from the GSVT class, was 89.94%.DiscussionMany researchers have attempted to develop an arrhythmia detection system using deep learning architectures.", [["arrhythmia", "DISEASE", 138, 148], ["The lowest sensitivity performance", "TEST", 0, 34], ["an arrhythmia detection system", "PROBLEM", 135, 165], ["deep learning architectures", "TREATMENT", 172, 199], ["arrhythmia", "OBSERVATION", 138, 148]]], ["They used different data sources and approaches for this task.", [["this task", "TEST", 52, 61]]], ["We intend to explore this further using a new DL model in future work.", [["a new DL model", "TREATMENT", 40, 54]]], ["In addition, many of the studies [4, 5, 30, 58, 59, 61, 65, 67] are predicated on the detection of heartbeat signals, unlike in our model, which is based on the 10-second ECG input.DiscussionThe main advantages of the system presented in this study can be summarized as:Discussion\uf0b7 Only one DNN model was used to classify different rhythm groups with high performance using all lead signals.Discussion\uf0b7 We used a public ECG dataset, which is recent, and one of the largest datasets, containing more than 10,000 unique subject data.Discussion\uf0b7 The experiments were performed using 11 different rhythm categories with 10-sec ECG records.Discussion\uf0b7 All experimental results were reported with inter-patient schema, and the performance of the model was promising.Discussion\uf0b7 The model has a good generalization ability to detect ECG arrhythmia for each of 12lead ECG signals.Discussion\uf0b7 The model worked on 10-second ECG records and did not require the detection of heartbeats.DiscussionThe main disadvantage of this work is the requirement for sophisticated hardware due to the nature of the deep models.", [["arrhythmia", "DISEASE", 830, 840], ["the studies", "TEST", 21, 32], ["heartbeat signals", "TEST", 99, 116], ["a public ECG dataset", "TEST", 411, 431], ["ECG arrhythmia", "PROBLEM", 826, 840], ["heartbeats", "PROBLEM", 963, 973], ["sophisticated hardware", "TREATMENT", 1042, 1064], ["hardware", "OBSERVATION", 1056, 1064], ["deep", "ANATOMY_MODIFIER", 1090, 1094]]], ["In future works, we will evaluate these ECG records with multitask deep learning models.", [["these ECG", "TEST", 34, 43]]], ["In addition, some features in non-ECG domains were also provided within this database, and we will try to use these features to improve the performance of deep models.ConclusionIn this paper, a new DNN model comprising both representation and sequence learning structures was proposed to detect arrhythmia.", [["arrhythmia", "DISEASE", 295, 305], ["non-ECG domains", "DNA", 30, 45], ["DNN model", "DNA", 198, 207], ["some features in non-ECG domains", "PROBLEM", 13, 45], ["a new DNN model", "PROBLEM", 192, 207], ["arrhythmia", "PROBLEM", 295, 305]]], ["Experiments were performed on a new large public ECG database that includes more than 10,000 unique subject records.", [["a new large public ECG database", "TEST", 30, 61]]], ["The DNN model was applied to the 10-s raw 12-lead ECG signals.", [["DNN model", "CELL_LINE", 4, 13], ["The DNN model", "TREATMENT", 0, 13]]], ["The proposed DNN model yielded promising results for each lead input.", [["DNN model", "CELL_LINE", 13, 22], ["each lead input", "TREATMENT", 53, 68]]], ["Two different rhythm class scenarios were used for the experiments.", [["rhythm", "OBSERVATION", 14, 20], ["class scenarios", "OBSERVATION", 21, 36]]], ["The first scenario included seven rhythm classes, for which the model obtained an accuracy of 92.24%.", [["an accuracy", "TEST", 79, 90]]], ["In the second scenario, 11 rhythm classes were merged into four main rhythm classes.", [["main", "OBSERVATION_MODIFIER", 64, 68], ["rhythm classes", "OBSERVATION", 69, 83]]], ["The model achieved an accuracy of 96.13% performance on this dataset.ConclusionAccording to the obtained results, it can be said that the proposed DNN model has a good generalization ability for subject-wise classes.", [["DNN model", "CELL_LINE", 147, 156], ["an accuracy", "TEST", 19, 30]]]], "PMC6696700": [["IntroductionWorldwide, infectious diseases continue to emerge at an alarming pace, due to numerous factors including microbial adaptation, increasing human population migration, urbanization, conflict and instability, intensified animal-human interface, and habitat perturbation [1\u20136].", [["infectious diseases", "DISEASE", 23, 42], ["human", "ORGANISM", 150, 155], ["human", "ORGANISM", 237, 242], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 237, 242], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 237, 242], ["infectious diseases", "PROBLEM", 23, 42], ["an alarming pace", "TREATMENT", 65, 81], ["numerous factors", "PROBLEM", 90, 106], ["microbial adaptation", "PROBLEM", 117, 137], ["increasing human population migration", "TREATMENT", 139, 176], ["instability", "PROBLEM", 205, 216], ["infectious", "OBSERVATION", 23, 33]]], ["The litmus test for an effective national public health program is its ability to be ready to initiate an effective response for an unknown emerging or re-emerging infectious disease or public health event.", [["The litmus test", "TEST", 0, 15], ["re-emerging infectious disease", "PROBLEM", 152, 182]]], ["The most impactful global health programs are built with the understanding that they must be able to help countries strengthen core public health capacity so that new threats can be detected and contained before they become international crises that increase morbidity and mortality, adversely impact the health and livelihoods of individuals and populations, disrupt travel, interfere with global trade and economies, or even lead to political destabilization [6, 7].IntroductionThis is the basis for all global health security work and has been the mission of CDC\u2019s Global Disease Detection (GDD) program since its inception in 2004.", [["Global Disease Detection (GDD) program", "PROBLEM", 568, 606]]], ["As one of the first steps through which CDC systematically approached global health security, the GDD program was designed to bring resources together to promote a broader approach to preparing countries for any infectious disease threat that could occur [8].", [["a broader approach", "TREATMENT", 162, 180], ["any infectious disease threat", "PROBLEM", 208, 237]]], ["Today, after more than a decade of partnerships in groundbreaking science, disease detection, and response to the world\u2019s most urgent public health threats, lessons from the GDD program as a precursor to global health security offer the global health community one model for collective success.", [["disease detection", "PROBLEM", 75, 92], ["the GDD program", "TREATMENT", 170, 185]]], ["This supplement is dedicated to highlighting a sample of successes achieved and lessons learned through the GDD program throughout its 10+ years of implementation.GDD and Global Health security ::: Beginnings and principlesGlobal health preparedness is a priority worldwide, as evidenced by the adoption of the International Health Regulations (IHR) in 2005, and the subsequent work of over 60 nations, the U.S. Government, CDC, the World Health Organization (WHO), to advance the Global Health Security Agenda (GHSA) [14].", [["GDD", "DISEASE", 163, 166], ["the GDD program", "TREATMENT", 104, 119]]], ["GHSA, launched in February 2014, is a commitment between countries to marshal resources, expertise, and technical assistance to build core public health infrastructure around the world and monitor progress using specific metrics and targets.GDD and Global Health security ::: Beginnings and principlesThe ultimate goal of the GHSA is to better prepare for epidemics and pandemics and to help countries meet their commitments to the WHO IHR, 2005 [15] and the World Organization of Animal Health\u2019s (OIE) Performance of Veterinary Services Pathway [16].", [["GDD", "DISEASE", 241, 244], ["epidemics", "PROBLEM", 356, 365]]], ["The GDD program\u2019s value in helping countries achieve IHR goals was solidified in December 2009, when the program \u2013 although a relatively small program with a modest budget \u2013 was designated by WHO as a Collaborating Center for Implementation of IHR National Surveillance and Response Capacity [17].GDD and Global Health security ::: Beginnings and principlesThe GDD program contributes to global health security efforts in much the same way as GHSA by strengthening the world\u2019s core public health capacity, ultimately helping countries achieve IHR compliance.", [["GDD", "DISEASE", 297, 300], ["GHSA", "CHEMICAL", 443, 447], ["The GDD program", "TREATMENT", 357, 372], ["IHR compliance", "TREATMENT", 543, 557]]], ["Each outbreak response corresponded to a specific event regardless of the number of cases identified during the outbreak \u2013 for example, a single case of rabies and an outbreak of dengue resulting in 8000 cases were both considered single outbreak events.", [["rabies", "DISEASE", 153, 159], ["dengue", "DISEASE", 179, 185], ["rabies", "ORGANISM", 153, 159], ["rabies", "SPECIES", 153, 159], ["dengue", "SPECIES", 179, 185], ["dengue", "PROBLEM", 179, 185], ["single outbreak events", "PROBLEM", 231, 253]]], ["Outbreaks also included events in animals, such as H5N1 in poultry, West Nile Virus in horses, and rabies in dogs, as well as responses related to the environment such as pesticide poisonings and natural disasters.", [["H5N1", "DISEASE", 51, 55], ["Nile Virus", "DISEASE", 73, 83], ["rabies", "DISEASE", 99, 105], ["poisonings", "DISEASE", 181, 191], ["H5N1", "ORGANISM", 51, 55], ["West Nile Virus", "ORGANISM", 68, 83], ["horses", "ORGANISM", 87, 93], ["dogs", "ORGANISM", 109, 113], ["H5N1", "SPECIES", 51, 55], ["poultry", "SPECIES", 59, 66], ["Nile Virus", "SPECIES", 73, 83], ["horses", "SPECIES", 87, 93], ["dogs", "SPECIES", 109, 113], ["poultry", "SPECIES", 59, 66], ["West Nile Virus", "SPECIES", 68, 83], ["horses", "SPECIES", 87, 93], ["rabies", "SPECIES", 99, 105], ["H5N1", "PROBLEM", 51, 55]]], ["One quarter (509 of 2051) of all outbreaks that GDD RCs responded to between 2006 and 2016 occurred outside of the GDD RCs\u2019 countries of origin (Fig. 2).Outbreak response ::: A look at the data: GDD program activities and accomplishmentsAmong one of the most important contributions of the GDD RCs have been responses during the recent WHO-declared Public Health Events of International Concern (PHEICs).", [["GDD", "DISEASE", 48, 51], ["the GDD RCs", "PROBLEM", 286, 297]]], ["Shortly after the April 2009 declaration of H1N1 as a PHEIC, GDD RCs in Egypt, Guatemala, Kazakhstan, Kenya, and Thailand partnered with 57 countries to improve and/or establish diagnostic laboratory capacity to detect H1N1 (Fig. 3); 46 of these (80%) partnerships or interactions occurred from May 1\u2013June 1, 2009.Outbreak response ::: A look at the data: GDD program activities and accomplishmentsDuring the 2014\u20132015 Ebola outbreak in West Africa, all 10 GDD RCs, as well as CDC Headquarters in Atlanta, deployed GDD program personnel to aid in the response effort (Fig. 4).", [["H1N1", "DISEASE", 44, 48], ["H1N1", "DISEASE", 219, 223], ["Ebola", "DISEASE", 419, 424], ["H1N1", "PROBLEM", 44, 48], ["diagnostic laboratory capacity", "TEST", 178, 208], ["H1N1", "PROBLEM", 219, 223], ["GDD program personnel", "TREATMENT", 515, 536]]], ["In addition, 13 of the 45 (29%) individuals deployed were host country nationals or locally employed staff.Outbreak response ::: A look at the data: GDD program activities and accomplishmentsGDD RCs not only directly supported Ebola response efforts but also prepared their respective and neighboring countries for possible importation and spread of the virus within their borders.", [["Ebola", "DISEASE", 227, 232], ["individuals", "ORGANISM", 32, 43], ["Ebola", "ORGANISM", 227, 232], ["the virus", "PROBLEM", 350, 359]]], ["Using an assessment tool developed by CDC, GDD Guatemala conducted an Ebola preparedness assessment for 12 Latin American nations, while GDD Egypt trained 13 participants from Jordan, Morocco, Lebanon, Tunisia, and Egypt on Ebola preparedness.", [["Ebola", "DISEASE", 224, 229], ["Ebola", "ORGANISM", 224, 229], ["participants", "SPECIES", 158, 170], ["an assessment tool", "TEST", 6, 24], ["an Ebola preparedness assessment", "TEST", 67, 99], ["Ebola preparedness", "TREATMENT", 224, 242]]], ["GDD Bangladesh collaborated with a large number of non-governmental private sector groups to develop standard operating procedures for Ebola case management and response; similarly, GDD Thailand collaborated with health ministers from 13 countries to develop a strategic framework for enhancing partnership on Ebola preparedness and response.", [["Ebola", "DISEASE", 135, 140], ["Ebola", "DISEASE", 310, 315], ["Ebola", "ORGANISM", 135, 140], ["Ebola", "ORGANISM", 310, 315], ["Ebola", "SPECIES", 310, 315], ["standard operating procedures", "TREATMENT", 101, 130], ["Ebola case management", "TREATMENT", 135, 156], ["Ebola preparedness", "TREATMENT", 310, 328]]], ["Laboratory testing capacity for Ebola was increased by GDD India, and airport screening protocols and border security were improved by GDD Kenya.", [["Ebola", "DISEASE", 32, 37], ["Ebola", "ORGANISM", 32, 37], ["Ebola", "SPECIES", 32, 37], ["Laboratory testing capacity", "TEST", 0, 27], ["Ebola", "PROBLEM", 32, 37], ["airport screening protocols", "TEST", 70, 97]]], ["Meanwhile, GDD RCs in South Africa and China focused on increasing communication platforms for the dissemination of information concerning Ebola.", [["Ebola", "DISEASE", 139, 144], ["Ebola", "ORGANISM", 139, 144], ["increasing communication platforms", "TREATMENT", 56, 90], ["Ebola", "PROBLEM", 139, 144], ["Ebola", "OBSERVATION", 139, 144]]], ["Furthermore, the Chinese Field Epidemiology Training Program (FETP) deployed 23 current and former trainees for the first time and U.S. CDC locally engaged country staff were deployed to Sierra Leone to help transfer laboratory technology to the Chinese laboratory in-country.Outbreak response ::: A look at the data: GDD program activities and accomplishmentsThe GDD RCs were well poised to act during the 2014\u20132017 Zika epidemic.", [["Zika", "DISEASE", 417, 421], ["The GDD RCs", "TEST", 360, 371]]], ["Using a combination of funding sources, including Zika supplemental funding provided through partnership with the US Agency for International Development and GDD core funding, eight of the 10 GDD RCs (Guatemala, Kenya, Thailand, South Africa, India, Bangladesh, China, and Egypt) were able to use their existing acute febrile illness surveillance systems to implement a global, network-wide surveillance activity to examine the global distribution of Zika virus.", [["febrile illness", "DISEASE", 318, 333], ["Zika virus", "ORGANISM", 451, 461], ["Zika virus", "SPECIES", 451, 461], ["funding sources", "TREATMENT", 23, 38], ["Zika supplemental funding", "TREATMENT", 50, 75], ["GDD core funding", "TREATMENT", 158, 174], ["acute febrile illness surveillance systems", "PROBLEM", 312, 354], ["Zika virus", "PROBLEM", 451, 461], ["Zika virus", "OBSERVATION", 451, 461]]], ["The timely introduction of Zika testing into existing GDD supported surveillance platforms allowed for the rapid identification and characterization of some of the first Zika cases in Guatemala and India [18].", [["Zika testing", "TEST", 27, 39], ["surveillance platforms", "TEST", 68, 90], ["the rapid identification", "TEST", 103, 127]]], ["The Guatemala, Kenya, and Thailand RCs were also able to quickly design and implement studies to examine the effect of Zika virus infection in pregnant women and their babies, and the Guatemala RC was able to initiate activities to examine potential long-term outcomes of infection.", [["Zika virus infection", "DISEASE", 119, 139], ["infection", "DISEASE", 272, 281], ["Zika virus", "ORGANISM", 119, 129], ["women", "ORGANISM", 152, 157], ["women", "SPECIES", 152, 157], ["Zika virus", "SPECIES", 119, 129], ["implement studies", "TEST", 76, 93], ["Zika virus infection", "PROBLEM", 119, 139], ["infection", "PROBLEM", 272, 281], ["infection", "OBSERVATION", 272, 281]]], ["Leveraging existing platforms allowed for faster implementation of activities.", [["Leveraging existing platforms", "TEST", 0, 29]]], ["It also generated important lessons for future responses, such as the need to consider how differences among protocols can affect comparability of results across countries, and highlighted the potential benefits of centralized coordination of surveillance and research.Laboratory capacity ::: A look at the data: GDD program activities and accomplishmentsOne of the strengths of the GDD RCs has been their ability to increase laboratory capacity for identification of threats, including identifying new pathogens to the world or pathogens new to a region.Laboratory capacity ::: A look at the data: GDD program activities and accomplishmentsOf the 2051 outbreak responses, the GDD RCs provided laboratory support in 1363 (66%).", [["surveillance", "TEST", 243, 255], ["Laboratory capacity", "TEST", 269, 288], ["laboratory capacity", "TEST", 426, 445], ["new pathogens", "PROBLEM", 499, 512], ["pathogens", "PROBLEM", 529, 538], ["Laboratory capacity", "TEST", 555, 574], ["laboratory support", "TREATMENT", 694, 712]]], ["Of these 1363 laboratory-supported outbreak responses, 1153 (85%) resulted in a confirmed etiology or cause of the outbreak.", [["the outbreak", "PROBLEM", 111, 123], ["outbreak", "OBSERVATION", 115, 123]]], ["In the same 10-year period, 381 pathogen-specific tests were newly established or updated by GDD RCs in 62 countries through a program of deliberate technology transfer.", [["specific tests", "TEST", 41, 55]]], ["Examples included tests for pathogens of international concern or pandemic potential (e.g. H1N1, H5N1, H7N9, MERS coronavirus, chikungunya, and Ebola), respiratory pathogens (e.g. adenovirus, rhinovirus, coronavirus, and RSV), acute febrile illness pathogens (e.g. Q Fever/Coxiella burnetii, Leptospirosis, Brucella, Rickettsia, and West Nile Virus), food and waterborne pathogens (e.g. Escherichia coli, Salmonella, Shigella, Listeria, and Campylobacter), and others (e.g. Bartonella species, Botulinum neurotoxins, arboviruses, arenaviruses).Laboratory capacity ::: A look at the data: GDD program activities and accomplishmentsIn collaboration with local and international partners, GDD RCs conducted groundbreaking work on 79 organisms during 2007\u20132016, including detecting 62 organisms new to their respective regions, discovering 11 organisms and pathogens new to the world, and identifying 5 pathogens with a new mode of transmission (Table 1).", [["H5N1", "DISEASE", 97, 101], ["MERS coronavirus, chikungunya, and Ebola)", "DISEASE", 109, 150], ["respiratory pathogens", "DISEASE", 152, 173], ["adenovirus, rhinovirus, coronavirus, and RSV)", "DISEASE", 180, 225], ["febrile illness", "DISEASE", 233, 248], ["Leptospirosis", "DISEASE", 292, 305], ["waterborne pathogens", "DISEASE", 360, 380], ["Botulinum neurotoxins", "DISEASE", 494, 515], ["arboviruses", "DISEASE", 517, 528], ["arenaviruses", "DISEASE", 530, 542], ["H5N1", "ORGANISM", 97, 101], ["MERS coronavirus", "ORGANISM", 109, 125], ["chikungunya", "ORGANISM", 127, 138], ["Ebola", "ORGANISM", 144, 149], ["adenovirus", "ORGANISM", 180, 190], ["rhinovirus", "ORGANISM", 192, 202], ["coronavirus", "ORGANISM", 204, 215], ["RSV", "ORGANISM", 221, 224], ["Coxiella burnetii", "ORGANISM", 273, 290], ["West Nile Virus", "ORGANISM", 333, 348], ["Escherichia coli", "ORGANISM", 387, 403], ["Salmonella", "ORGANISM", 405, 415], ["Shigella, Listeria", "ORGANISM", 417, 435], ["Bartonella species", "ORGANISM", 474, 492], ["Botulinum neurotoxins", "ORGANISM", 494, 515], ["arenaviruses", "ORGANISM", 530, 542], ["H5N1", "SPECIES", 97, 101], ["MERS coronavirus", "SPECIES", 109, 125], ["Ebola", "SPECIES", 144, 149], ["Coxiella burnetii", "SPECIES", 273, 290], ["West Nile Virus", "SPECIES", 333, 348], ["Escherichia coli", "SPECIES", 387, 403], ["H7N9", "SPECIES", 103, 107], ["MERS coronavirus", "SPECIES", 109, 125], ["RSV", "SPECIES", 221, 224], ["Coxiella burnetii", "SPECIES", 273, 290], ["West Nile Virus", "SPECIES", 333, 348], ["Escherichia coli", "SPECIES", 387, 403], ["tests", "TEST", 18, 23], ["pathogens", "PROBLEM", 28, 37], ["H1N1", "PROBLEM", 91, 95], ["H5N1", "PROBLEM", 97, 101], ["H7N9", "PROBLEM", 103, 107], ["MERS coronavirus", "PROBLEM", 109, 125], ["chikungunya", "PROBLEM", 127, 138], ["Ebola", "PROBLEM", 144, 149], ["respiratory pathogens", "PROBLEM", 152, 173], ["adenovirus", "PROBLEM", 180, 190], ["rhinovirus", "PROBLEM", 192, 202], ["coronavirus", "PROBLEM", 204, 215], ["RSV", "PROBLEM", 221, 224], ["acute febrile illness pathogens", "PROBLEM", 227, 258], ["Fever", "PROBLEM", 267, 272], ["Coxiella burnetii", "PROBLEM", 273, 290], ["Leptospirosis", "PROBLEM", 292, 305], ["Brucella", "PROBLEM", 307, 315], ["Rickettsia", "PROBLEM", 317, 327], ["West Nile Virus", "PROBLEM", 333, 348], ["food and waterborne pathogens", "PROBLEM", 351, 380], ["Escherichia coli", "PROBLEM", 387, 403], ["Salmonella", "PROBLEM", 405, 415], ["Shigella", "PROBLEM", 417, 425], ["Listeria", "PROBLEM", 427, 435], ["Campylobacter", "PROBLEM", 441, 454], ["Bartonella species", "PROBLEM", 474, 492], ["Botulinum neurotoxins", "PROBLEM", 494, 515], ["arboviruses", "PROBLEM", 517, 528], ["arenaviruses", "PROBLEM", 530, 542], ["Laboratory capacity", "TEST", 544, 563], ["11 organisms", "PROBLEM", 836, 848], ["pathogens", "PROBLEM", 853, 862], ["5 pathogens", "PROBLEM", 897, 908], ["respiratory", "ANATOMY", 152, 163], ["RSV", "ANATOMY", 221, 224], ["acute", "OBSERVATION_MODIFIER", 227, 232], ["febrile", "OBSERVATION_MODIFIER", 233, 240]]], ["Examples of pathogens new to their respective regions included novel influenza viruses (H1N1, H5N1, H3N2, H9N2), arboviruses (dengue serotype 3, Chikungunya virus, Zika virus, West Nile virus, Tahyna virus, Babanki virus, Ndumu virus, Sindbis-like virus, Usutu virus, Sandfly fever Sicilian virus) [19, 20], and bacterial and parasitic pathogens (Q fever/Coxiella burnetii, Leishmania species, and Legionella longbeacheae) [21].Surveillance, epidemiology, and data capacity ::: A look at the data: GDD program activities and accomplishmentsIn 2017, the GDD program began collecting data on the number and type of surveillance platforms and the number of people enrolled or captured in active or passive disease surveillance systems.", [["influenza viruses", "DISEASE", 69, 86], ["H1N1, H5N1, H3N2, H9N2), arboviruses", "DISEASE", 88, 124], ["dengue", "DISEASE", 126, 132], ["Chikungunya virus", "DISEASE", 145, 162], ["Sandfly fever", "DISEASE", 268, 281], ["bacterial and parasitic pathogens", "DISEASE", 312, 345], ["Q fever", "DISEASE", 347, 354], ["influenza viruses", "ORGANISM", 69, 86], ["H1N1, H5N1, H3N2, H9N2", "ORGANISM", 88, 110], ["dengue serotype 3", "ORGANISM", 126, 143], ["Chikungunya virus", "ORGANISM", 145, 162], ["Zika virus", "ORGANISM", 164, 174], ["West Nile virus", "ORGANISM", 176, 191], ["Tahyna virus", "ORGANISM", 193, 205], ["Babanki virus", "ORGANISM", 207, 220], ["Ndumu virus", "ORGANISM", 222, 233], ["Sindbis-like virus", "ORGANISM", 235, 253], ["Usutu virus", "ORGANISM", 255, 266], ["Sandfly fever Sicilian virus", "ORGANISM", 268, 296], ["Q fever", "ORGANISM", 347, 354], ["Coxiella burnetii", "ORGANISM", 355, 372], ["Leishmania species", "ORGANISM", 374, 392], ["Legionella longbeacheae", "ORGANISM", 398, 421], ["people", "ORGANISM", 654, 660], ["H5N1", "SPECIES", 94, 98], ["H3N2, H9N2", "SPECIES", 100, 110], ["dengue serotype", "SPECIES", 126, 141], ["Chikungunya virus", "SPECIES", 145, 162], ["Zika virus", "SPECIES", 164, 174], ["West Nile virus", "SPECIES", 176, 191], ["Tahyna virus", "SPECIES", 193, 205], ["Babanki virus", "SPECIES", 207, 220], ["Ndumu virus", "SPECIES", 222, 233], ["Sindbis-like virus", "SPECIES", 235, 253], ["Usutu virus", "SPECIES", 255, 266], ["Sandfly fever", "SPECIES", 268, 281], ["Sicilian virus", "SPECIES", 282, 296], ["Q fever", "SPECIES", 347, 354], ["Coxiella burnetii", "SPECIES", 355, 372], ["Legionella longbeacheae", "SPECIES", 398, 421], ["people", "SPECIES", 654, 660], ["dengue serotype 3", "SPECIES", 126, 143], ["Chikungunya virus", "SPECIES", 145, 162], ["Zika virus", "SPECIES", 164, 174], ["West Nile virus", "SPECIES", 176, 191], ["Tahyna virus", "SPECIES", 193, 205], ["Babanki virus", "SPECIES", 207, 220], ["Ndumu virus", "SPECIES", 222, 233], ["Sindbis-like virus", "SPECIES", 235, 253], ["Usutu virus", "SPECIES", 255, 266], ["Sandfly fever Sicilian virus", "SPECIES", 268, 296], ["Coxiella burnetii", "SPECIES", 355, 372], ["Legionella longbeacheae", "SPECIES", 398, 421], ["pathogens", "PROBLEM", 12, 21], ["novel influenza viruses", "PROBLEM", 63, 86], ["H1N1", "PROBLEM", 88, 92], ["H5N1", "PROBLEM", 94, 98], ["H3N2", "PROBLEM", 100, 104], ["H9N2", "PROBLEM", 106, 110], ["arboviruses (dengue serotype", "PROBLEM", 113, 141], ["Chikungunya virus", "PROBLEM", 145, 162], ["Zika virus", "PROBLEM", 164, 174], ["West Nile virus", "TEST", 176, 191], ["Tahyna virus", "PROBLEM", 193, 205], ["Babanki virus", "PROBLEM", 207, 220], ["Ndumu virus", "PROBLEM", 222, 233], ["Sindbis", "TEST", 235, 242], ["like virus", "PROBLEM", 243, 253], ["Usutu virus", "PROBLEM", 255, 266], ["Sandfly fever Sicilian virus", "PROBLEM", 268, 296], ["bacterial and parasitic pathogens", "PROBLEM", 312, 345], ["fever", "PROBLEM", 349, 354], ["Coxiella burnetii", "PROBLEM", 355, 372], ["Leishmania species", "PROBLEM", 374, 392], ["surveillance platforms", "TEST", 613, 635], ["passive disease surveillance systems", "PROBLEM", 695, 731], ["pathogens", "OBSERVATION", 12, 21], ["influenza viruses", "OBSERVATION", 69, 86], ["parasitic pathogens", "OBSERVATION", 326, 345], ["Leishmania species", "OBSERVATION", 374, 392], ["active", "OBSERVATION_MODIFIER", 685, 691], ["passive disease", "OBSERVATION", 695, 710]]], ["GDD RCs\u2019 activities currently cover more than 109,000,000 people through various types of surveillance platforms.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64], ["GDD RCs\u2019 activities", "TREATMENT", 0, 19], ["surveillance platforms", "TEST", 90, 112]]], ["GDD RCs have established more than 288 unique surveillance sites monitoring disease syndromes and specific illnesses such as acute febrile illness, respiratory disease, Japanese Encephalitis, and Nipah Virus.", [["respiratory", "ANATOMY", 148, 159], ["acute febrile illness", "DISEASE", 125, 146], ["respiratory disease", "DISEASE", 148, 167], ["Japanese Encephalitis", "DISEASE", 169, 190], ["Nipah Virus", "DISEASE", 196, 207], ["Nipah Virus", "ORGANISM", 196, 207], ["Nipah", "SPECIES", 196, 201], ["Nipah Virus", "SPECIES", 196, 207], ["GDD RCs", "PROBLEM", 0, 7], ["disease syndromes", "PROBLEM", 76, 93], ["specific illnesses", "PROBLEM", 98, 116], ["acute febrile illness", "PROBLEM", 125, 146], ["respiratory disease", "PROBLEM", 148, 167], ["Japanese Encephalitis", "PROBLEM", 169, 190], ["Nipah Virus", "PROBLEM", 196, 207], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["respiratory disease", "OBSERVATION", 148, 167], ["Nipah Virus", "OBSERVATION", 196, 207]]], ["The syndrome most commonly responded to by GDD RCs from 2007 to 2016 was gastrointestinal illness (diarrhea, vomiting), followed by influenza-like illness (ILI) and acute/undifferentiated febrile illness (A/UFI).", [["gastrointestinal", "ANATOMY", 73, 89], ["gastrointestinal illness", "DISEASE", 73, 97], ["diarrhea", "DISEASE", 99, 107], ["vomiting", "DISEASE", 109, 117], ["influenza-like illness", "DISEASE", 132, 154], ["ILI", "DISEASE", 156, 159], ["acute/undifferentiated febrile illness", "DISEASE", 165, 203], ["gastrointestinal", "ORGAN", 73, 89], ["The syndrome", "PROBLEM", 0, 12], ["gastrointestinal illness", "PROBLEM", 73, 97], ["diarrhea", "PROBLEM", 99, 107], ["vomiting", "PROBLEM", 109, 117], ["influenza", "PROBLEM", 132, 141], ["acute/undifferentiated febrile illness", "PROBLEM", 165, 203], ["syndrome", "OBSERVATION", 4, 12], ["gastrointestinal", "ANATOMY", 73, 89], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["undifferentiated", "OBSERVATION_MODIFIER", 171, 187], ["febrile", "OBSERVATION", 188, 195]]], ["Increased ILI cases in 2009 were due to the pandemic of H1N1 and outbreaks of H5N1, while increased gastrointestinal illnesses in 2013 corresponded to cases of cholera in Kenya, and increased A/UFI in 2014 correlated with the dengue and chikungunya outbreaks in East Africa.Surveillance, epidemiology, and data capacity ::: A look at the data: GDD program activities and accomplishmentsThe types of disease surveillance platforms implemented via the GDD RCs include event-based, sentinel, facility-based, and population-based surveillance.", [["gastrointestinal", "ANATOMY", 100, 116], ["ILI", "DISEASE", 10, 13], ["H1N1", "DISEASE", 56, 60], ["H5N1", "DISEASE", 78, 82], ["gastrointestinal illnesses", "DISEASE", 100, 126], ["cholera", "DISEASE", 160, 167], ["dengue", "DISEASE", 226, 232], ["chikungunya", "DISEASE", 237, 248], ["gastrointestinal", "ORGAN", 100, 116], ["H5N1", "SPECIES", 78, 82], ["dengue", "SPECIES", 226, 232], ["Increased ILI cases", "PROBLEM", 0, 19], ["H1N1", "PROBLEM", 56, 60], ["H5N1", "PROBLEM", 78, 82], ["increased gastrointestinal illnesses", "PROBLEM", 90, 126], ["cholera", "PROBLEM", 160, 167], ["the dengue", "PROBLEM", 222, 232], ["chikungunya", "PROBLEM", 237, 248], ["disease surveillance platforms", "PROBLEM", 399, 429], ["the GDD RCs", "TREATMENT", 446, 457], ["surveillance", "TEST", 526, 538], ["H1N1", "OBSERVATION", 56, 60], ["H5N1", "OBSERVATION", 78, 82], ["gastrointestinal", "ANATOMY", 100, 116], ["chikungunya", "OBSERVATION", 237, 248], ["disease", "OBSERVATION", 399, 406]]], ["The ability to conduct population-based surveillance is particularly important because it often provides the most accurate information on the burden of infectious disease syndromes, as it allows for the calculation of their incidence, which is the number of cases among a known population size during a standard period of time.", [["infectious disease syndromes", "DISEASE", 152, 180], ["infectious disease syndromes", "PROBLEM", 152, 180], ["infectious", "OBSERVATION", 152, 162], ["population", "OBSERVATION_MODIFIER", 278, 288], ["size", "OBSERVATION_MODIFIER", 289, 293]]], ["GDD RCs in China, Egypt, Guatemala, India, Kenya and Thailand have conducted population-based surveillance over the course of the 10-year period [22\u201327].", [["GDD RCs", "PROBLEM", 0, 7], ["China", "ANATOMY", 11, 16]]], ["The incidence rates generated via these platforms are important measures of disease burden because they can be compared across different locales.", [["The incidence rates", "PROBLEM", 0, 19], ["disease burden", "PROBLEM", 76, 90]]], ["Examples of uses of data derived from population-based surveillance include the comparison of rates of disease in rural areas with rates in urban areas and the monitoring of impact of interventions or control strategies.Workforce development ::: A look at the data: GDD program activities and accomplishmentsThe GDD program recognizes that a strong workforce lies at the core of effective emergency response.", [["disease in rural areas", "PROBLEM", 103, 125], ["interventions", "TREATMENT", 184, 197], ["control strategies", "TREATMENT", 201, 219], ["disease", "OBSERVATION", 103, 110]]], ["The subject matter experts from across CDC headquarters, as well as highly trained medical epidemiologists, laboratorians, veterinarians, and public health specialists stationed within the GDD RCs lead formal training programs, such as the Field Epidemiology Training Program (FETP), offer informal on-the-job-training and provide mentorship to local counterparts [28].", [["formal training programs", "TREATMENT", 202, 226]]], ["In addition to leading training opportunities such as tabletop exercises and data analysis workshops, GDD RCs capitalize on CDC subject matter expertise around the agency to provide disease-specific guidance and training.", [["tabletop exercises", "TREATMENT", 54, 72], ["data analysis", "TEST", 77, 90], ["GDD RCs", "TREATMENT", 102, 109]]], ["This development of workforce capacity at the local level is integral to identifying and containing public health threats at their source.Workforce development ::: A look at the data: GDD program activities and accomplishmentsThe graduates of FETPs in GDD RCs from 2006 to 2016 responded to many of the outbreaks recorded, leading to proper identification of the source for many of the outbreaks, detection of additional cases/determining the full scope of the outbreaks, and classification or discovery of existing or novel risk factors of disease transmission.", [["workforce capacity", "PROBLEM", 20, 38], ["FETPs in GDD RCs", "PROBLEM", 243, 259], ["disease transmission", "PROBLEM", 541, 561]]], ["More often than not, these graduates continue to practice public health in-country after graduating [28].Research and support ::: A look at the data: GDD program activities and accomplishmentsGDD RCs served as the platform for subject matter experts and researchers across CDC and through their effort provided a total of 4253 public health consultations from 2006 to 2016.", [["GDD program activities", "TEST", 150, 172], ["accomplishmentsGDD RCs", "TREATMENT", 177, 199]]], ["For example, GDD Kenya regularly provided consultations on health issues affecting refugees in Kenya, Ethiopia, Uganda, and Tanzania, while GDD India teamed up with the National Institute of Mental Health and Allied Sciences (NIMHANS) to work on an acute encephalitis syndrome network.", [["acute encephalitis syndrome", "DISEASE", 249, 276], ["an acute encephalitis syndrome network", "PROBLEM", 246, 284], ["acute", "OBSERVATION_MODIFIER", 249, 254], ["encephalitis", "OBSERVATION", 255, 267]]], ["Regional Centers such as GDD Egypt, GDD Kazakhstan, and GDD Georgia conducted laboratory assessments at laboratories and hospitals, recommended laboratory equipment for national blood banks, and advised on infection control procedures, respectively, with subject matter expertise support from CDC headquarters.Research and support ::: A look at the data: GDD program activities and accomplishmentsFurthermore, the GDD RCs supported the use of technology by collaborating with provincial satellite TV channels to communicate risks such as hand, foot, and mouth disease (HFMD) and H1N1 in Vietnam \u2013 as was the case with GDD China \u2013 and by providing technical support for an electronic surveillance platform in Panama, coordinated out of the GDD RC in Guatemala.", [["blood", "ANATOMY", 178, 183], ["hand", "ANATOMY", 538, 542], ["foot", "ANATOMY", 544, 548], ["mouth", "ANATOMY", 554, 559], ["infection", "DISEASE", 206, 215], ["hand, foot, and mouth disease", "DISEASE", 538, 567], ["HFMD", "DISEASE", 569, 573], ["H1N1", "DISEASE", 579, 583], ["blood", "ORGANISM_SUBSTANCE", 178, 183], ["hand", "ORGANISM_SUBDIVISION", 538, 542], ["foot", "ORGANISM_SUBDIVISION", 544, 548], ["mouth", "ORGAN", 554, 559], ["GDD Egypt", "PROBLEM", 25, 34], ["GDD Kazakhstan", "TREATMENT", 36, 50], ["laboratory assessments", "TEST", 78, 100], ["national blood banks", "TEST", 169, 189], ["infection control procedures", "TREATMENT", 206, 234], ["hand, foot, and mouth disease", "PROBLEM", 538, 567], ["H1N1", "PROBLEM", 579, 583], ["foot", "ANATOMY", 544, 548], ["mouth", "ANATOMY", 554, 559]]], ["These publications address disease-specific outbreaks and emergencies, surveillance and laboratory science, and cross-cutting priorities related to disease threats.", [["disease", "PROBLEM", 27, 34], ["surveillance", "TEST", 71, 83], ["laboratory science", "TEST", 88, 106], ["disease threats", "PROBLEM", 148, 163]]], ["These publications show the diversity and strong scientific foundations of GDD\u2019s work.One tested model for the future of global health security ::: Discussion and lessons learnedThe GDD program\u2019s efforts over the last decade to improve global public health capacity have, indeed, moved us forward.", [["strong", "OBSERVATION_MODIFIER", 42, 48]]], ["A major success of the GDD program has been to create regional platforms where subject matter experts can engage with one another and programs can break free of their silos.", [["the GDD program", "TREATMENT", 19, 34]]], ["From the beginning, the GDD program has applied a consistent set of goals and metrics to track progress over time and across programs.", [["the GDD program", "TREATMENT", 20, 35]]], ["Over the past few years, the WHO Joint External Evaluations have become a valuable tool to track progress on global health security initiatives, both past-to-present and country-to-country [29].", [["External Evaluations", "TEST", 39, 59], ["Joint", "ANATOMY", 33, 38]]], ["Evaluation is a key part of recognizing accomplishments and is critical to finding gaps we must still address.", [["Evaluation", "TEST", 0, 10]]], ["Only once we know where we stand can we take action to implement successful programs and point them in the right direction to reduce our identified vulnerabilities.Deploy the power of science and data.", [["successful programs", "TREATMENT", 65, 84], ["right", "ANATOMY_MODIFIER", 107, 112], ["power", "OBSERVATION_MODIFIER", 175, 180]]], ["Cutting-edge scientific research has always been at the core of the GDD program\u2019s mission.", [["edge", "OBSERVATION_MODIFIER", 8, 12]]], ["Scientific research helps partners make evidence-based decisions and implement effective local solutions that eliminate outbreaks at their source.", [["effective local solutions", "TREATMENT", 79, 104]]], ["The GDD program\u2019s success has relied on strong partnerships.", [["The GDD program", "TREATMENT", 0, 15]]], ["The program\u2019s longstanding presence in regions across the globe has proven that in-country engagement leads to trust.", [["regions", "ANATOMY_MODIFIER", 39, 46], ["globe", "ANATOMY", 58, 63]]], ["Strong partnerships at all levels are critical to global health security, and the process of creating GDD RCs has formed and strengthened partnerships at all levels \u2013 government-to-government relationships, collaboration with other organizations and non-governmental organizations (NGOs), and local and personal connections \u2013 that can be leveraged to address critical public health priorities.Build for flexibility.", [["creating GDD RCs", "PROBLEM", 93, 109]]], ["Cross-cutting public health programs give us the ability to respond to any crisis, regardless of cause.", [["Cross-cutting public health programs", "TREATMENT", 0, 36], ["any crisis", "PROBLEM", 71, 81]]], ["As threats change, and as science changes, funding tied to a single disease may prove limiting in its scope.", [["a single disease", "PROBLEM", 59, 75]]], ["Flexible, nimble systems are our best answer to an unpredictable future.Ongoing challenges ::: Discussion and lessons learnedWhile there have been many successes and substantial impacts made by GDD RCs, there have also been significant challenges recognized.", [["Flexible, nimble systems", "TREATMENT", 0, 24], ["GDD RCs", "TREATMENT", 194, 201], ["many", "OBSERVATION_MODIFIER", 147, 151], ["successes", "OBSERVATION", 152, 161], ["substantial", "OBSERVATION_MODIFIER", 166, 177], ["significant", "OBSERVATION_MODIFIER", 224, 235], ["challenges", "OBSERVATION", 236, 246]]], ["Some of these have impacted the ability of the GDD program to accomplish one of its primary goals: helping countries achieve IHR compliance.Ongoing challenges ::: Discussion and lessons learnedDespite the global prominence of infectious diseases, there are few rigorous and precise estimates of the burden and etiology of key infectious disease syndromes in developing countries [30, 31].", [["infectious diseases", "DISEASE", 226, 245], ["infectious disease syndromes", "DISEASE", 326, 354], ["the GDD program", "TREATMENT", 43, 58], ["IHR compliance", "TREATMENT", 125, 139], ["infectious diseases", "PROBLEM", 226, 245], ["the burden", "PROBLEM", 295, 305], ["key infectious disease syndromes", "PROBLEM", 322, 354], ["global", "OBSERVATION_MODIFIER", 205, 211], ["prominence", "OBSERVATION_MODIFIER", 212, 222], ["infectious", "OBSERVATION", 226, 236], ["few", "OBSERVATION_MODIFIER", 257, 260], ["rigorous", "OBSERVATION_MODIFIER", 261, 269], ["infectious", "OBSERVATION_MODIFIER", 326, 336]]], ["Some of the problems in measuring the burden of these diseases in developing countries have included poor access to the clinical facilities, lack of accurate or available laboratory diagnostics, and absence of population-based surveillance systems needed to accurately assess incidence rates.", [["the problems", "PROBLEM", 8, 20], ["these diseases", "PROBLEM", 48, 62], ["laboratory diagnostics", "TEST", 171, 193], ["surveillance systems", "TEST", 227, 247], ["diseases", "OBSERVATION", 54, 62]]], ["Accurate information on burden of the most important infectious disease syndromes is needed by ministries of health and public health policy decision-makers to set current priorities for optimal use of limited resources for public health programs.", [["infectious disease syndromes", "DISEASE", 53, 81], ["infectious disease syndromes", "PROBLEM", 53, 81], ["public health programs", "TREATMENT", 224, 246]]], ["Efforts to assist our partner countries in building national laboratory and surveillance systems have been significantly hampered by insufficient resource allocation \u2013 both financial and staff time.", [["surveillance systems", "TEST", 76, 96]]], ["This has led to a greater recognition of the actual time and money required to develop and maintain such systems.Ongoing challenges ::: Discussion and lessons learnedAnother challenge has been the need for better coordination and communication of a unified mission and objective that is supported, fully adopted and implemented in all of the GDD RCs.", [["the GDD RCs", "TREATMENT", 338, 349]]], ["In some instances, lack of clarity on adopting and implementing a unified mission led to a divergence of operations and a mixture of activities driven, in many cases, by individual investigator interests and expertise in country.", [["operations", "TREATMENT", 105, 115]]], ["The public health science conducted through such activities has been commendable; however, the data generated has not always been completely successful in informing policy for ministries of health (i.e., vaccine coverage, educational campaigns targeting high-risk populations, improvement or development of vector-control programs).", [["vaccine coverage", "TREATMENT", 204, 220], ["educational campaigns", "TREATMENT", 222, 243], ["high-risk populations", "TREATMENT", 254, 275], ["vector-control programs", "TREATMENT", 307, 330]]], ["More needs to be done to ensure that data are applied to their full potential in improving the health of the populations served.Ongoing challenges ::: Discussion and lessons learnedFinally, although there have been some cross GDD RC projects (e.g., Use of a multipathogen Taqman Array Card to identify the etiology of community-acquired pneumonia, C. Van Beneden pers com), overall, it has been a challenge for the GDD RCs to link across a network of regional offices or platforms to implement unified protocols or projects (i.e. estimating burden of a specific disease, measuring the effect of a specific medical countermeasure, etc.) in multiple countries, throughout multiple populations, in diverse ecologies, and among unique cultural settings.", [["pneumonia", "DISEASE", 337, 346], ["C. Van Beneden pers", "SPECIES", 348, 367], ["community-acquired pneumonia", "PROBLEM", 318, 346], ["the GDD RCs", "TREATMENT", 411, 422], ["unified protocols", "TREATMENT", 494, 511], ["a specific disease", "PROBLEM", 551, 569], ["a specific medical countermeasure", "TREATMENT", 595, 628], ["pneumonia", "OBSERVATION", 337, 346]]], ["Building the capacity to do this could strengthen the overall goals of global health security to prevent, detect and respond to health threats.ConclusionThe GDD program is part of a long and significant history at CDC of protecting health globally, ranging from smallpox eradication, polio elimination, HIV, malaria, and cholera control to emergencies including SARS, H1N1, Ebola, and Zika.", [["smallpox", "DISEASE", 262, 270], ["polio elimination, HIV, malaria", "DISEASE", 284, 315], ["cholera", "DISEASE", 321, 328], ["SARS, H1N1, Ebola, and Zika", "DISEASE", 362, 389], ["Ebola", "ORGANISM", 374, 379], ["HIV", "SPECIES", 303, 306], ["HIV", "SPECIES", 303, 306], ["smallpox eradication", "TREATMENT", 262, 282], ["polio elimination", "PROBLEM", 284, 301], ["HIV", "PROBLEM", 303, 306], ["malaria", "PROBLEM", 308, 315], ["cholera control", "TREATMENT", 321, 336], ["SARS", "PROBLEM", 362, 366], ["H1N1", "PROBLEM", 368, 372], ["Ebola", "PROBLEM", 374, 379], ["Zika", "PROBLEM", 385, 389]]], ["The nature of disease means that we cannot always predict what the next outbreak will be, or where and how it will spread.", [["disease", "PROBLEM", 14, 21], ["disease", "OBSERVATION", 14, 21]]], ["Ever-increasing interconnection across the globe means that when the next outbreak does take hold, it will be capable of spreading rapidly.", [["increasing", "OBSERVATION_MODIFIER", 5, 15], ["interconnection", "OBSERVATION", 16, 31], ["globe", "ANATOMY", 43, 48]]], ["To stop it, we will need systems in place that are sensitive enough to signal a new health threat, specific enough to pinpoint problems and focus resources, and flexible and connected enough to protect the world\u2019s economic and social wellbeing.", [["systems", "TREATMENT", 25, 32]]], ["We must recognize that global health security begins locally \u2013 if there are gaps anywhere in the system, disease will find it.ConclusionLessons learned through the lens of the GDD program can offer us a way forward.", [["disease", "PROBLEM", 105, 112], ["the GDD program", "TREATMENT", 172, 187]]], ["These strategies include increasing coordinated, multi-center scientific collaboration across nations to strengthen the global network; increasing the number of public health professionals trained; broadening and strengthening global partnerships; and reducing gaps in global preparedness for emerging health threats.ConclusionAs the global health community looks for the best ways to operate in our changing world, lessons from the GDD program will continue to inform our work.", [["increasing coordinated", "PROBLEM", 25, 47], ["increasing", "OBSERVATION_MODIFIER", 25, 35], ["coordinated", "OBSERVATION_MODIFIER", 36, 47]]]], "0ab25ba570e745ff6a63051a301a7ee9e0c23910": [["pression that liver failure is not a main concern and this organ is not the target of significant inflammatory damage.", [["liver", "ANATOMY", 14, 19], ["organ", "ANATOMY", 59, 64], ["liver failure", "DISEASE", 14, 27], ["liver", "ORGAN", 14, 19], ["organ", "ORGAN", 59, 64], ["liver failure", "PROBLEM", 14, 27], ["significant inflammatory damage", "PROBLEM", 86, 117], ["liver", "ANATOMY", 14, 19], ["failure", "OBSERVATION", 20, 27], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["inflammatory", "OBSERVATION_MODIFIER", 98, 110], ["damage", "OBSERVATION", 111, 117]]], ["Histopathological findings are highly suggestive for marked derangement of intrahepatic blood vessel network secondary to systemic changes induced by virus that could target not only lung parenchyma but also car- Bergamo, a city located in north of Italy not far from Milan, became quickly the epicenter of the Italian COVID-19 outbreak.", [["intrahepatic blood vessel network", "ANATOMY", 75, 108], ["lung parenchyma", "ANATOMY", 183, 198], ["derangement of intrahepatic blood vessel", "DISEASE", 60, 100], ["intrahepatic blood vessel network", "MULTI-TISSUE_STRUCTURE", 75, 108], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 183, 198], ["Histopathological findings", "TEST", 0, 26], ["marked derangement of intrahepatic blood vessel network", "PROBLEM", 53, 108], ["systemic changes", "PROBLEM", 122, 138], ["virus", "PROBLEM", 150, 155], ["highly suggestive for", "UNCERTAINTY", 31, 52], ["marked", "OBSERVATION_MODIFIER", 53, 59], ["derangement", "OBSERVATION", 60, 71], ["intrahepatic", "ANATOMY_MODIFIER", 75, 87], ["blood vessel", "ANATOMY", 88, 100], ["systemic", "OBSERVATION", 122, 130], ["virus", "OBSERVATION", 150, 155], ["lung", "ANATOMY", 183, 187], ["parenchyma", "ANATOMY_MODIFIER", 188, 198]]], ["Up to the end of March 2020 more than 9000 people were infected and at least 2500 persons died.", [["people", "ORGANISM", 43, 49], ["persons", "ORGANISM", 82, 89], ["people", "SPECIES", 43, 49], ["persons", "SPECIES", 82, 89]]], ["Even the area of Milan registered a high number of infected people.", [["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66], ["area", "OBSERVATION_MODIFIER", 9, 13], ["high", "OBSERVATION_MODIFIER", 36, 40], ["number", "OBSERVATION_MODIFIER", 41, 47], ["infected", "OBSERVATION", 51, 59]]]], "c174154a11e936304af52d8a722b3ce75f27bb31": [["IntroductionDiseases prevalent in the tropics present with varied manifestations compared to diseases that occur commonly in temperate climates like in the West.", [["IntroductionDiseases", "DISEASE", 0, 20], ["IntroductionDiseases", "TREATMENT", 0, 20], ["varied manifestations", "PROBLEM", 59, 80], ["diseases", "PROBLEM", 93, 101]]], ["Tropical diseases contribute to significant mortality and morbidity.", [["Tropical diseases", "PROBLEM", 0, 17], ["significant mortality", "PROBLEM", 32, 53], ["morbidity", "PROBLEM", 58, 67], ["diseases", "OBSERVATION", 9, 17], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["mortality", "OBSERVATION", 44, 53], ["morbidity", "OBSERVATION", 58, 67]]], ["If diagnosed at the right time, tropical diseases have good prognosis too.", [["tropical diseases", "PROBLEM", 32, 49], ["right", "ANATOMY_MODIFIER", 20, 25]]], ["Utilizing the useful function of supporting the cardio-pulmonary status in these critically ill disease states would save thousands of lives each year.", [["pulmonary", "ANATOMY", 55, 64], ["critically ill", "DISEASE", 81, 95], ["pulmonary", "ORGAN", 55, 64], ["cardio", "ANATOMY", 48, 54], ["pulmonary", "ANATOMY", 55, 64]]], ["As these diseases are not frequent in the West, apart from reporting the experiences in the form of an anecdotal case, much guidance is not available in their management.", [["diseases", "OBSERVATION", 9, 17]]], ["We hold the great responsibility of providing the world with guidance on managing these tropical diseases on ECMO.", [["these tropical diseases", "PROBLEM", 82, 105], ["ECMO", "TREATMENT", 109, 113]]], ["Some of the examples are: Severe malaria with ARDS, Tuberculosis with secondary infections, Typhus fevers, Rickettsiosis, ARDS in H1N1, Middle East Respiratory Distress Syndrome (MERS) virus and similar viral infections, Chagas disease, Legionellosis, Envenomations such as Scorpion sting with severe vaso-dilatory shock, Snake bites, Myocarditis due to Dengue, Diphtheria, Scrub typhus, Poisonings etc. The list could be longer and these patients could be supported with the underlying understanding of managing the reversible phase of these critically ill diseases with ECMO support when they don't respond to maximal conventional management (Table 1) .Infections presenting as ARDSA variety of bacterial and viral infections present with an ARDS picture in tropical countries.", [["malaria", "DISEASE", 33, 40], ["ARDS", "DISEASE", 46, 50], ["Tuberculosis", "DISEASE", 52, 64], ["secondary infections", "DISEASE", 70, 90], ["Typhus fevers", "DISEASE", 92, 105], ["Rickettsiosis", "DISEASE", 107, 120], ["ARDS", "DISEASE", 122, 126], ["Middle East Respiratory Distress Syndrome", "DISEASE", 136, 177], ["MERS) virus", "DISEASE", 179, 190], ["viral infections", "DISEASE", 203, 219], ["Chagas disease", "DISEASE", 221, 235], ["Legionellosis", "DISEASE", 237, 250], ["Envenomations", "DISEASE", 252, 265], ["Scorpion sting", "DISEASE", 274, 288], ["vaso-dilatory shock", "DISEASE", 301, 320], ["Snake bites", "DISEASE", 322, 333], ["Myocarditis", "DISEASE", 335, 346], ["Dengue", "DISEASE", 354, 360], ["Diphtheria", "DISEASE", 362, 372], ["Scrub typhus", "DISEASE", 374, 386], ["critically ill", "DISEASE", 543, 557], ["Infections", "DISEASE", 655, 665], ["bacterial and viral infections", "DISEASE", 697, 727], ["ARDS", "DISEASE", 744, 748], ["Middle East Respiratory Distress", "ORGANISM", 136, 168], ["Scrub typhus", "ORGANISM", 374, 386], ["patients", "ORGANISM", 439, 447], ["patients", "SPECIES", 439, 447], ["Middle East Respiratory Distress Syndrome (MERS) virus", "SPECIES", 136, 190], ["Severe malaria", "PROBLEM", 26, 40], ["ARDS", "PROBLEM", 46, 50], ["Tuberculosis", "PROBLEM", 52, 64], ["secondary infections", "PROBLEM", 70, 90], ["Typhus fevers", "PROBLEM", 92, 105], ["Rickettsiosis", "PROBLEM", 107, 120], ["ARDS", "PROBLEM", 122, 126], ["H1N1", "PROBLEM", 130, 134], ["Middle East Respiratory Distress Syndrome", "PROBLEM", 136, 177], ["MERS) virus", "PROBLEM", 179, 190], ["similar viral infections", "PROBLEM", 195, 219], ["Chagas disease", "PROBLEM", 221, 235], ["Legionellosis", "PROBLEM", 237, 250], ["Envenomations", "PROBLEM", 252, 265], ["Scorpion sting", "PROBLEM", 274, 288], ["severe vaso-dilatory shock", "PROBLEM", 294, 320], ["Snake bites", "PROBLEM", 322, 333], ["Myocarditis", "PROBLEM", 335, 346], ["Dengue", "PROBLEM", 354, 360], ["Diphtheria", "PROBLEM", 362, 372], ["Scrub typhus", "PROBLEM", 374, 386], ["these critically ill diseases", "PROBLEM", 537, 566], ["ECMO support", "TREATMENT", 572, 584], ["maximal conventional management", "TREATMENT", 612, 643], ["Infections", "PROBLEM", 655, 665], ["bacterial and viral infections", "PROBLEM", 697, 727], ["an ARDS picture", "PROBLEM", 741, 756], ["Severe", "OBSERVATION_MODIFIER", 26, 32], ["malaria", "OBSERVATION", 33, 40], ["ARDS", "OBSERVATION", 46, 50], ["Tuberculosis", "OBSERVATION", 52, 64], ["secondary", "OBSERVATION_MODIFIER", 70, 79], ["infections", "OBSERVATION", 80, 90], ["Typhus", "OBSERVATION_MODIFIER", 92, 98], ["Rickettsiosis", "OBSERVATION", 107, 120], ["ARDS", "OBSERVATION", 122, 126], ["H1N1", "OBSERVATION", 130, 134], ["Middle", "ANATOMY_MODIFIER", 136, 142], ["Respiratory Distress", "OBSERVATION", 148, 168], ["viral", "OBSERVATION_MODIFIER", 203, 208], ["infections", "OBSERVATION", 209, 219], ["Chagas disease", "OBSERVATION", 221, 235], ["Legionellosis", "OBSERVATION", 237, 250], ["dilatory shock", "OBSERVATION", 306, 320], ["Myocarditis", "OBSERVATION", 335, 346], ["bacterial", "OBSERVATION_MODIFIER", 697, 706], ["viral", "OBSERVATION_MODIFIER", 711, 716], ["infections", "OBSERVATION", 717, 727], ["ARDS", "OBSERVATION", 744, 748]]], ["Besides the usual gram positive infections, increasing number of gram negative organisms are being reported as causative organisms.", [["gram positive infections", "DISEASE", 18, 42], ["the usual gram positive infections", "PROBLEM", 8, 42], ["gram negative organisms", "PROBLEM", 65, 88], ["causative organisms", "PROBLEM", 111, 130], ["positive", "OBSERVATION_MODIFIER", 23, 31], ["infections", "OBSERVATION", 32, 42], ["increasing", "OBSERVATION_MODIFIER", 44, 54], ["number", "OBSERVATION_MODIFIER", 55, 61], ["gram negative", "OBSERVATION_MODIFIER", 65, 78], ["organisms", "OBSERVATION", 79, 88]]], ["Management of multi-drug resistant strains and variability in availability of pure drug formulations might contribute to additional challenges.", [["Management", "TREATMENT", 0, 10], ["multi-drug resistant strains", "PROBLEM", 14, 42], ["pure drug formulations", "TREATMENT", 78, 100], ["resistant strains", "OBSERVATION", 25, 42]]], ["In-fact, infections are responsible for 20% increase in the mortality rate in ECMO outcomes compared to the western world [1] .", [["infections", "DISEASE", 9, 19], ["infections", "PROBLEM", 9, 19], ["ECMO outcomes", "TREATMENT", 78, 91], ["infections", "OBSERVATION", 9, 19]]], ["When gas exchange can't be achieved with maximal conventional management, ECMO would be a potential option in these reversible conditions.", [["maximal conventional management", "TREATMENT", 41, 72], ["ECMO", "TREATMENT", 74, 78], ["these reversible conditions", "PROBLEM", 110, 137]]], ["In diseases such as Pulmonary/Miliary Tuberculosis, onset of secondary infections are sometimes responsible for life threatening ARDS.", [["Pulmonary", "ANATOMY", 20, 29], ["Pulmonary/Miliary Tuberculosis", "DISEASE", 20, 50], ["infections", "DISEASE", 71, 81], ["ARDS", "DISEASE", 129, 133], ["Pulmonary/Miliary Tuberculosis", "PROBLEM", 20, 50], ["secondary infections", "PROBLEM", 61, 81], ["life threatening ARDS", "PROBLEM", 112, 133], ["diseases", "OBSERVATION", 3, 11], ["Pulmonary", "ANATOMY", 20, 29], ["Miliary", "OBSERVATION_MODIFIER", 30, 37], ["Tuberculosis", "OBSERVATION", 38, 50], ["secondary", "OBSERVATION_MODIFIER", 61, 70], ["infections", "OBSERVATION", 71, 81]]], ["Other known viral infections such as Respiratory Syncytial virus and Adenovirus are not only universally ubiquitous, but are also known to co-exist with other bacterial and viral infections.Production and hosting by ElsevierMalaria has been predominant world-wide, however more so in tropical countries.", [["viral infections", "DISEASE", 12, 28], ["Respiratory Syncytial virus", "DISEASE", 37, 64], ["viral infections", "DISEASE", 173, 189], ["ElsevierMalaria", "CHEMICAL", 216, 231], ["Respiratory Syncytial virus", "ORGANISM", 37, 64], ["Adenovirus", "ORGANISM", 69, 79], ["Respiratory Syncytial virus", "SPECIES", 37, 64], ["Respiratory Syncytial virus", "SPECIES", 37, 64], ["Adenovirus", "SPECIES", 69, 79], ["Other known viral infections", "PROBLEM", 0, 28], ["Respiratory Syncytial virus", "PROBLEM", 37, 64], ["Adenovirus", "PROBLEM", 69, 79], ["other bacterial and viral infections", "PROBLEM", 153, 189], ["viral", "OBSERVATION_MODIFIER", 12, 17], ["infections", "OBSERVATION", 18, 28], ["Respiratory Syncytial virus", "OBSERVATION", 37, 64], ["Adenovirus", "OBSERVATION", 69, 79], ["viral", "OBSERVATION_MODIFIER", 173, 178], ["infections", "OBSERVATION", 179, 189], ["predominant", "OBSERVATION_MODIFIER", 241, 252], ["wide", "OBSERVATION_MODIFIER", 259, 263]]], ["Severe malaria presenting with ARDS (unresponsive to maximal conventional management) may present as a reversible condition on ECMO.Production and hosting by ElsevierThere are many infections noticeable particularly in the tropical world, of which the physician should be vigilant about and consider wider differential diagnosis under different geographical conditions.", [["malaria", "DISEASE", 7, 14], ["ARDS", "DISEASE", 31, 35], ["infections", "DISEASE", 181, 191], ["Severe malaria", "PROBLEM", 0, 14], ["ARDS", "PROBLEM", 31, 35], ["maximal conventional management", "TREATMENT", 53, 84], ["a reversible condition", "PROBLEM", 101, 123], ["ECMO", "TREATMENT", 127, 131], ["many infections", "PROBLEM", 176, 191], ["malaria", "OBSERVATION", 7, 14], ["ARDS", "OBSERVATION", 31, 35], ["many", "OBSERVATION_MODIFIER", 176, 180], ["infections", "OBSERVATION", 181, 191]]], ["Any of the following conditions presenting with Severe ARDS unresponsive to maximal conventional treatment or severe sepsis will be an indication for ECMO support while awaiting the medications to act and the underlying process to resolve.", [["ARDS", "DISEASE", 55, 59], ["sepsis", "DISEASE", 117, 123], ["Severe ARDS", "PROBLEM", 48, 59], ["maximal conventional treatment", "TREATMENT", 76, 106], ["severe sepsis", "PROBLEM", 110, 123], ["ECMO support", "TREATMENT", 150, 162], ["the medications", "TREATMENT", 178, 193], ["Severe", "OBSERVATION_MODIFIER", 48, 54], ["ARDS", "OBSERVATION", 55, 59], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["sepsis", "OBSERVATION", 117, 123]]], ["In our experience, pertussis is one of the most difficult infections to be treated on ECMO [6] (Table 2 ).MyocarditisTropical: Infections and bites from venomous animals such as Scorpions and Snakes can be transiently supported on ECMO while awaiting the effects of the causative agent to be neutralized.MyocarditisMyocarditis secondary to Dengue [7] and Enterovirus [8] have been successfully treated on ECMO unless the myocardium doesn't recover within 10 days.", [["myocardium", "ANATOMY", 421, 431], ["pertussis", "DISEASE", 19, 28], ["infections", "DISEASE", 58, 68], ["Infections and bites", "DISEASE", 127, 147], ["Myocarditis", "DISEASE", 304, 315], ["Myocarditis", "DISEASE", 315, 326], ["Dengue", "DISEASE", 340, 346], ["myocardium", "ORGAN", 421, 431], ["pertussis", "PROBLEM", 19, 28], ["difficult infections", "PROBLEM", 48, 68], ["ECMO", "TREATMENT", 86, 90], ["Infections", "PROBLEM", 127, 137], ["bites", "PROBLEM", 142, 147], ["venomous animals", "PROBLEM", 153, 169], ["ECMO", "TREATMENT", 231, 235], ["the causative agent", "TREATMENT", 266, 285], ["MyocarditisMyocarditis", "PROBLEM", 304, 326], ["Dengue", "PROBLEM", 340, 346], ["Enterovirus", "PROBLEM", 355, 366], ["ECMO", "TREATMENT", 405, 409], ["infections", "OBSERVATION", 58, 68], ["Infections", "OBSERVATION", 127, 137], ["myocardium", "ANATOMY", 421, 431]]], ["In cases requiring prolonged ECMO, transition to a ventricular assist devise would be an option.", [["ventricular", "ANATOMY", 51, 62], ["ventricular", "MULTI-TISSUE_STRUCTURE", 51, 62], ["prolonged ECMO", "TREATMENT", 19, 33], ["a ventricular assist devise", "TREATMENT", 49, 76]]], ["Wide geographical areas such as deserts and forests infested with poisonous scorpions, spiders and snakes, the resulting myocarditis or vasodilatory shock could be supported on ECMO [9] .PoisoningsUnfortunately, poisonings are ubiquitous in South Asia and West Asia.", [["poisonous scorpions", "DISEASE", 66, 85], ["myocarditis", "DISEASE", 121, 132], ["shock", "DISEASE", 149, 154], ["poisonings", "DISEASE", 212, 222], ["Wide geographical areas", "PROBLEM", 0, 23], ["poisonous scorpions", "PROBLEM", 66, 85], ["the resulting myocarditis", "PROBLEM", 107, 132], ["vasodilatory shock", "PROBLEM", 136, 154], ["ECMO", "TREATMENT", 177, 181], ["geographical", "OBSERVATION_MODIFIER", 5, 17], ["areas", "OBSERVATION_MODIFIER", 18, 23], ["myocarditis", "OBSERVATION", 121, 132], ["vasodilatory shock", "OBSERVATION", 136, 154]]], ["One such scenario resulting from Celphos poisoning has been successfully treated on ECMO support given that patients are brought to centers having access to ECMO [10] .", [["Celphos", "CHEMICAL", 33, 40], ["poisoning", "DISEASE", 41, 50], ["Celphos", "CHEMICAL", 33, 40], ["ECMO", "CHEMICAL", 157, 161], ["Celphos", "SIMPLE_CHEMICAL", 33, 40], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["Celphos poisoning", "PROBLEM", 33, 50], ["ECMO support", "TREATMENT", 84, 96], ["ECMO", "TREATMENT", 157, 161]]], ["This principle applies to management of any similar condition which is transitory and expected to get better with support on ECMO.PoisoningsThere is a huge need for bringing this modality of healthcare to the majority of needy people in these resource limited countries.", [["people", "ORGANISM", 227, 233], ["people", "SPECIES", 227, 233], ["management", "TREATMENT", 26, 36], ["any similar condition", "PROBLEM", 40, 61], ["ECMO", "TREATMENT", 125, 129]]]]}